A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer
Identifieur interne : 000A85 ( Pmc/Corpus ); précédent : 000A84; suivant : 000A86A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer
Auteurs : Tuo Ruan ; Weizhen Liu ; Kaixiong Tao ; Chuanqing WuSource :
- OncoTargets and therapy [ 1178-6930 ] ; 2020.
Abstract
Gastric cancer is one of the most common malignant tumors, and it is also one of the leading causes of cancer death worldwide. Because of its insidious symptoms and lack of early dictation screening, many cases of gastric cancer are at late stages which make it more complicated to cure. For these advanced-stage gastric cancers, combination therapy of surgery, chemotherapy, radiotherapy and target therapy would bring more benefit to the patients. However, the drug-resistance to the chemotherapy restricts its effect and might lead to treatment failure. In this review article, we discuss the mechanisms which have been found in recent years of drug resistance in gastric cancer. And we also want to find new approaches to counteract chemotherapy resistance and bring more benefits to the patients.
Url:
DOI: 10.2147/OTT.S239336
PubMed: 32184615
PubMed Central: 7053652
Links to Exploration step
PMC:7053652Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer</title><author><name sortKey="Ruan, Tuo" sort="Ruan, Tuo" uniqKey="Ruan T" first="Tuo" last="Ruan">Tuo Ruan</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Liu, Weizhen" sort="Liu, Weizhen" uniqKey="Liu W" first="Weizhen" last="Liu">Weizhen Liu</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Tao, Kaixiong" sort="Tao, Kaixiong" uniqKey="Tao K" first="Kaixiong" last="Tao">Kaixiong Tao</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Wu, Chuanqing" sort="Wu, Chuanqing" uniqKey="Wu C" first="Chuanqing" last="Wu">Chuanqing Wu</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32184615</idno><idno type="pmc">7053652</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053652</idno><idno type="RBID">PMC:7053652</idno><idno type="doi">10.2147/OTT.S239336</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000A85</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer</title><author><name sortKey="Ruan, Tuo" sort="Ruan, Tuo" uniqKey="Ruan T" first="Tuo" last="Ruan">Tuo Ruan</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Liu, Weizhen" sort="Liu, Weizhen" uniqKey="Liu W" first="Weizhen" last="Liu">Weizhen Liu</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Tao, Kaixiong" sort="Tao, Kaixiong" uniqKey="Tao K" first="Kaixiong" last="Tao">Kaixiong Tao</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author><author><name sortKey="Wu, Chuanqing" sort="Wu, Chuanqing" uniqKey="Wu C" first="Chuanqing" last="Wu">Chuanqing Wu</name><affiliation><nlm:aff id="AFF0001"><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></nlm:aff></affiliation></author></analytic><series><title level="j">OncoTargets and therapy</title><idno type="eISSN">1178-6930</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Gastric cancer is one of the most common malignant tumors, and it is also one of the leading causes of cancer death worldwide. Because of its insidious symptoms and lack of early dictation screening, many cases of gastric cancer are at late stages which make it more complicated to cure. For these advanced-stage gastric cancers, combination therapy of surgery, chemotherapy, radiotherapy and target therapy would bring more benefit to the patients. However, the drug-resistance to the chemotherapy restricts its effect and might lead to treatment failure. In this review article, we discuss the mechanisms which have been found in recent years of drug resistance in gastric cancer. And we also want to find new approaches to counteract chemotherapy resistance and bring more benefits to the patients.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OTT</journal-id><journal-id journal-id-type="pmc">ott</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32184615</article-id><article-id pub-id-type="pmc">7053652</article-id><article-id pub-id-type="publisher-id">239336</article-id><article-id pub-id-type="doi">10.2147/OTT.S239336</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer</article-title><alt-title alt-title-type="running-authors">Ruan et al</alt-title><alt-title alt-title-type="running-title">Ruan et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ruan</surname><given-names>Tuo</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Weizhen</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Tao</surname><given-names>Kaixiong</given-names></name><xref ref-type="corresp" rid="AN0001"></xref><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Chuanqing</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><aff id="AFF0001"><label>1</label><institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>,<addr-line>Wuhan</addr-line><addr-line>430022</addr-line>,<country>China</country></aff></contrib-group><author-notes><corresp id="AN0001">Correspondence: Kaixiong Tao; Chuanqing Wu <institution>Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line><addr-line>430022</addr-line>, <country>China</country> Email tao_kaixiong@163.com; wucq2014@hust.edu.cn</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>13</volume><fpage>1797</fpage><lpage>1807</lpage><history><date date-type="received"><day>20</day><month>11</month><year>2019</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 Ruan et al.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Ruan et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>Gastric cancer is one of the most common malignant tumors, and it is also one of the leading causes of cancer death worldwide. Because of its insidious symptoms and lack of early dictation screening, many cases of gastric cancer are at late stages which make it more complicated to cure. For these advanced-stage gastric cancers, combination therapy of surgery, chemotherapy, radiotherapy and target therapy would bring more benefit to the patients. However, the drug-resistance to the chemotherapy restricts its effect and might lead to treatment failure. In this review article, we discuss the mechanisms which have been found in recent years of drug resistance in gastric cancer. And we also want to find new approaches to counteract chemotherapy resistance and bring more benefits to the patients.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>gastric cancer</kwd><kwd>chemotherapy</kwd><kwd>resistance</kwd></kwd-group><counts><fig-count count="1"></fig-count><ref-count count="141"></ref-count><page-count count="11"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Even with the development in medical detection and therapy, the morbidity of gastric cancer still remains to be ranking fourth in all cancers. And it is also the second cause of death due to cancers around the world. East Asian regions, especially China, Japan and Korea, are high-prevalence areas for gastric cancer.<xref rid="CIT0001" ref-type="bibr">1</xref> In China, gastric cancer is the second most common and deadliest cancer just after lung cancer in 2015. It has been estimated that there are over 700,000 new cases every year, and most of them are in rural area. On the other side, because of its insidious symptoms and lack of early dictation screening, many cases in China are at late stages which bring more difficulties to clinical treatments.<xref rid="CIT0002" ref-type="bibr">2</xref>,<xref rid="CIT0003" ref-type="bibr">3</xref> For advanced-stage gastric cancers, combination therapy of surgery, chemotherapy, radiotherapy and target therapy would bring more benefit to the patients.<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref> Chemotherapy is one of the main additional methods in treatment, but the rise of drug resistance restricts its effect and might lead to treatment failure.<xref rid="CIT0006" ref-type="bibr">6</xref>–<xref rid="CIT0008" ref-type="bibr">8</xref> In order to solve this problem, we need to study the mechanisms of the chemotherapy resistance and find solutions.</p><p>The mechanisms of drug resistance to chemotherapy are complex. According to what we have known, we conclude them into seven aspects as followed: (1) Reduce the effective concentration of intracellular drugs; (2) Change of drugs’ targets; (3) Dysfunction of DNA damage repairing; (4) Change of apoptosis and autophagy; (5) Change of tumor micro-environment; (6) Extracellular vesicles and macropinocytosis; (7) MicroRNAs and LncRNAs. Although we have made much progress in studying the molecular mechanisms of the drug resistance, it still lacks applied technique in detecting and controlling the chemotherapy resistance in clinical practice.<xref rid="CIT0009" ref-type="bibr">9</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref> In this article, we would like to summarize and analyze the research progress in chemotherapy in gastric cancer, and it might lead us to new solutions to this problem.</p></sec><sec id="S0002"><title>Reduce the Effective Concentration of Intracellular Drugs</title><sec id="S0002-S2001"><title>Drug Efflux</title><p>The ATP-binding cassette family is a group of the most well-known proteins in constructing transporters in cells.<xref rid="CIT0011" ref-type="bibr">11</xref>–<xref rid="CIT0013" ref-type="bibr">13</xref> These transporters will pump the drugs out of the cells and lead to multi-drug resistance. In these proteins, P-gp, ABCG2 and MRP-1 have been well studied in solid tumors, such as breast cancer, ovarian cancer and gastrointestinal cancers.<xref rid="CIT0014" ref-type="bibr">14</xref>–<xref rid="CIT0016" ref-type="bibr">16</xref> It has been proofed that P-gp is overexpressed in gastric cancer, and would be related to the poor prognosis of the patients.<xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0018" ref-type="bibr">18</xref> The expression of P-gp is also highly related to acquired drug resistance and the risk of relapse after chemotherapy which makes it important in our studies.<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref></p><p>The regulation pathways of P-gp in regulating drug resistance are diverse. MAPK pathway proteins play important roles as down-stream receptors and in regulating intracellular environment when P-gp is up-regulated in cancer cells.<xref rid="CIT0020" ref-type="bibr">20</xref> NF-κB could also enhance the expression of P-gp by targeted combining the promoter of P-gp gene to induce multi-drug resistance.<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref> On the other hand, inhibiting PI3K/AKT pathway could reduce the expression of P-gp and reverse drug resistance.<xref rid="CIT0023" ref-type="bibr">23</xref> The pathways and molecules which we have mentioned above could serve as targets for us to inhibit drug resistance and provide us with new solutions to this problem.<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0025" ref-type="bibr">25</xref></p></sec><sec id="S0002-S2002"><title>Drug Inactivation</title><p>Normal cells could decompose and transform the toxins and their intermediate products to detoxification in order to maintain stable homeostasis. This is also the way that cancer cells decrease the damage from chemotherapeutics.</p><p>Glutathione S-transferases (GST) are important in inactivating drugs and induce drug resistance. The main mechanisms are as followed: (1) Catalyze glutathione to combine with electrophilic substrates and prevent reactive oxygen species from causing damage to cell membranes; (2) Up-regulated glutathione and GST will enhance the polarity of drugs to make them inactive; (3) GST could also remove toxic metabolites directly to reduce damage.<xref rid="CIT0026" ref-type="bibr">26</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref> In some researches, we could find that the expression of GST is higher in cancer tissues than normal epithelium.<xref rid="CIT0028" ref-type="bibr">28</xref> Specifically, it has a strong connection with the drug resistance to platinum.<xref rid="CIT0029" ref-type="bibr">29</xref>,<xref rid="CIT0030" ref-type="bibr">30</xref></p></sec></sec><sec id="S0003"><title>Change of Drugs’ Targets</title><p>Tumor cells could reduce the level of drugs’ targets or enzymes’ activity in cells to induce drug resistance. DNA topoisomerase is served as drug targets by many commonly used chemotherapeutics, such as doxorubicin and etoposide. DNA topoisomerase is involved in DNA replication, recombination and repairing process of ribozymes. It is an important part in cell cycle regulation. There are two types of DNA topoisomerase isomers: topoisomerase I (Topo I) and topoisomerase II (Topo II). In gastric cancer, the expression of Topo II is up-regulated, and it has an influence on infiltration depth, histological type and lymph node metastasis. Topo II is also a key factor in inducing resistance to adriamycin and mitomycin C in gastric cancer, and it is correlated to prognosis.<xref rid="CIT0031" ref-type="bibr">31</xref>–<xref rid="CIT0034" ref-type="bibr">34</xref> Research has noticed that down-regulating the expression of Topo II would strengthen the resistance to adriamycin.<xref rid="CIT0035" ref-type="bibr">35</xref> This would lay the foundation for us to solve this kind of chemotherapy resistance.</p><p>With the development of new drugs and therapies, molecule-targeted therapy has become a hotspot in recent years for its higher efficiency and less side-effects.<xref rid="CIT0036" ref-type="bibr">36</xref>,<xref rid="CIT0037" ref-type="bibr">37</xref> In gastrointestinal cancers, imatinib has been widely used in curing GIST and has made great progress. It targets at tyrosine kinase to inhibit PDGF receptors, SCF and c-Kit receptors. While in clinical practice, we have found that the mutation of Kit and BRAF gene would lead to drug resistance to imatinib.<xref rid="CIT0038" ref-type="bibr">38</xref>,<xref rid="CIT0039" ref-type="bibr">39</xref> This situation demands us to study in the next generation of targeted drugs and make individual treatment more specific.</p></sec><sec id="S0004"><title>Dysfunction of DNA Damage Repairing</title><p>In normal cells, DNA damage repairing is activated when they have physical, chemical or biological damages in order to stabilize chromatin. However, when the repairing system is dysfunctional, it would lead to oncogenesis.<xref rid="CIT0040" ref-type="bibr">40</xref>,<xref rid="CIT0041" ref-type="bibr">41</xref> Chemotherapy utilizes DNA damage and cytotoxicity as an approach to kill cancer cells, especially for platinum drugs. Platinum inhibits DNA transcription and replication, and it might cause DNA cleavage which makes DNA damage repairing activation a key factor in drug resistance to platinum.<xref rid="CIT0042" ref-type="bibr">42</xref>,<xref rid="CIT0043" ref-type="bibr">43</xref></p><p>Nucleotide excision repair (NER) is an important pathway to repair the damage caused by chemotherapy drugs through identification, resection and reconstruction of damaged DNA. And this progress is composed of dozens of proteins.<xref rid="CIT0044" ref-type="bibr">44</xref>,<xref rid="CIT0045" ref-type="bibr">45</xref> While DNA mismatch repair genes (MMR), such as MLH1, also play a role in the development of gastric cancer and inducing drug resistance.<xref rid="CIT0046" ref-type="bibr">46</xref> These pathways could offer us a road to reverse drug resistance to platinum and bring benefits to the patients.</p></sec><sec id="S0005"><title>Change of Apoptosis and Autophagy</title><sec id="S0005-S2001"><title>Dysfunction of Apoptosis Pathways</title><p>There are two classical apoptosis pathways in human: (1) Endogenous pathway mediated by mitochondria; (2) Exogenous pathways mediated by tumor necrosis factor (TNF) receptors.<xref rid="CIT0047" ref-type="bibr">47</xref></p><p>The Bcl-2 protein family contains a variety of apoptosis-related proteins, such as Bax, Bad and Bid which induce apoptosis, and Bcl-2, Bcl-xl which inhibit the progress. These proteins interact with each other in order to maintain a relatively stable state for cells. When this balance is broken, it would likely lead to carcinogenesis and have resistance effects on chemotherapeutics which aim at inducing cell apoptosis.<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref> In gastric cancer, studies have shown that the over-expression of Bcl-2 is highly related to drug resistance, and it is also an important influence factor in prognosis.<xref rid="CIT0050" ref-type="bibr">50</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref> Bax, which is promoting apoptosis, has been confirmed to be used in predicting the patients’ response to chemotherapy.<xref rid="CIT0052" ref-type="bibr">52</xref> Upregulating the expression of Bax could help to promote sensitivity to chemotherapy in cancer cells by releasing cytochrome C from mitochondria.<xref rid="CIT0053" ref-type="bibr">53</xref> In addition, other members in the Bcl-2 family, such as Bcl-xL and Bak, also have been proved to be playing relevant roles in drug resistance.<xref rid="CIT0054" ref-type="bibr">54</xref>,<xref rid="CIT0055" ref-type="bibr">55</xref> These make Bcl-2 family critical in gastric cancer development and chemotherapy resistance. They would hopefully be a breakthrough point in our research.</p><p>Tumor necrosis factor (TNF) family proteins, such as NFRS-1, Fas, DR4 and DR5, are also important in cell apoptosis regulation. Studies have shown that Fas could induce cell apoptosis to eliminate tumor cells by combining with FasL, while the increase in soluble Fas will inhibit apoptosis.<xref rid="CIT0056" ref-type="bibr">56</xref>,<xref rid="CIT0057" ref-type="bibr">57</xref> A recent study has found that the expression of TNF-related apoptosis-inducing ligand (TRAIL) had a negative correlation with multidrug resistance-associated protein P-gp, and P-gp could achieve multi-drug resistance by regulating the expression of TRAIL and its mediated apoptosis pathway.<xref rid="CIT0058" ref-type="bibr">58</xref></p><p>P53 is one of the most popular tumor suppressor genes in our studies, and it has multiple functions in cell cycle regulation, DNA repairing and cell apoptosis. Researches have shown that p53 mutation is an important influence factor in gastric cancer development, and high expression of p53 gene is associated with poor prognosis.<xref rid="CIT0059" ref-type="bibr">59</xref>,<xref rid="CIT0060" ref-type="bibr">60</xref> At the same time, p53 also takes part in gastric cancer drug resistance. We could find that patients with mutant p53 have a better response to chemotherapy.<xref rid="CIT0061" ref-type="bibr">61</xref> And recent studies suggest that rAd-p53 could induce cell apoptosis in gastric cancer cells, and p53 could reverse cisplatin resistance by regulating the AKT signaling pathway and the expression of Bax.<xref rid="CIT0062" ref-type="bibr">62</xref>,<xref rid="CIT0063" ref-type="bibr">63</xref></p><p>PI3K/AKT pathway is crucial in cell growth and proliferation. Abnormal activation of the PI3K/AKT pathway has been reported to be one of the important mechanisms of inducing drug resistance in tumor cells.<xref rid="CIT0064" ref-type="bibr">64</xref>,<xref rid="CIT0065" ref-type="bibr">65</xref> And further studies have showed that some chemotherapeutics would activate the PI3K/AKT pathway which resulted in acquired drug resistance.<xref rid="CIT0066" ref-type="bibr">66</xref>,<xref rid="CIT0067" ref-type="bibr">67</xref> So far, the mechanisms of the PI3K/AKT pathway have not been fully understood. And the abnormal activation of the PI3K/AKT pathway in tumor cells might be via PI3K catalytic subunit of alpha (PIK3CA) mutation or loss of PTEN gene function.<xref rid="CIT0068" ref-type="bibr">68</xref>,<xref rid="CIT0069" ref-type="bibr">69</xref> NF-κB could serve as a down-stream targeted protein and take part in inducing drug resistance.<xref rid="CIT0070" ref-type="bibr">70</xref> P-gp, Bcl-2 and Bax could also be regulated by phosphorylated AKT.<xref rid="CIT0024" ref-type="bibr">24</xref> At the same time, how to make use of the PI3K/AKT pathway in clinical treatment is also on the schedule. Now, research has proved that the AKT inhibitor could reverse the drug resistance of gastric cancer cells.<xref rid="CIT0071" ref-type="bibr">71</xref> Further validation and application researches have been carried out and would get promising results for clinical works.<xref rid="CIT0072" ref-type="bibr">72</xref></p></sec><sec id="S0005-S2002"><title>Change of Autophagy Pathways</title><p>Autophagy is a cellular survival mechanism which is a highly conserved cellular process to degrade cytoplasmic materials and recycle to maintain energy homeostasis. And it could be induced by cancer therapy, among other stresses, and frequently contributes to cancer cell survival.<xref rid="CIT0073" ref-type="bibr">73</xref>–<xref rid="CIT0075" ref-type="bibr">75</xref> Autophagy can also be classified as macro-autophagy, micro-autophagy, and chaperone-mediated autophagy.</p><p>Molecular mechanisms of autophagy could be divided into initiation, nucleation and elongation of autophagosome, fusion of autophagosome with the lysosome, and degradation of sequestered material. Autophagy is constitutively activated in cancer cells through the deregulation of PI3K/Akt/mTOR molecular axis and AMP-activated protein kinase (AMPK) signal transduction, which contributes to the metabolic reprogramming of cancer cells.<xref rid="CIT0076" ref-type="bibr">76</xref>–<xref rid="CIT0078" ref-type="bibr">78</xref></p><p>A large amount of cancer therapies has been shown to induce autophagy, while many of them indicate that autophagy turns out to promote tumor cell survival and contribute to therapy resistance.<xref rid="CIT0079" ref-type="bibr">79</xref>,<xref rid="CIT0080" ref-type="bibr">80</xref> Some studies have also shown that autophagy-related proteins, such as Beclin 1 (BECN1), microtubule-associated protein1 light chain 3 (MAP1-LC3), and p62/sequestosome 1 (SQSTM1) have an important prognostic value in gastric cancer, and act as a protective mechanism for tumor cells in chemotherapy, promoting drug resistance as well.<xref rid="CIT0081" ref-type="bibr">81</xref>–<xref rid="CIT0083" ref-type="bibr">83</xref> The therapeutic induction of autophagy is frequently attributed to reduced mTOR activity leading to autophagy de-repression, and this is most obvious with therapies targeted at inhibiting PI3K, AKT or indeed mTOR itself. In addition, autophagy is induced by conventional genotoxic agents, such as radiation or cisplatin, as a result of DNA damage-induced p53 activity. However, the role of p53 in these responses is complicated. Depending on the context, it can also inhibit autophagy.<xref rid="CIT0084" ref-type="bibr">84</xref>,<xref rid="CIT0085" ref-type="bibr">85</xref> As there are a growing number of studies in autophagy and its cytoprotective effect, there might be a chance to help cancer therapeutic approaches with agents that inhibit autophagy.<xref rid="CIT0086" ref-type="bibr">86</xref>,<xref rid="CIT0087" ref-type="bibr">87</xref></p></sec></sec><sec id="S0006"><title>Change of Micro-Environment</title><p>There is extracellular matrix, a variety of trace elements, immune cells and other substances in tumor’s micro-environment. These substances have multiple effects on proliferation, invasion, metastasis and multi-drug resistance.<xref rid="CIT0088" ref-type="bibr">88</xref>–<xref rid="CIT0090" ref-type="bibr">90</xref></p><sec id="S0006-S2001"><title>Extracellular Matrix</title><p>Extracellular matrix is a complex network containing multifunctional molecules and has an important influence on tumor development. Laminin and collagen IV are important parts of the basement membrane in the gastric cancer’s extracellular matrix.<xref rid="CIT0091" ref-type="bibr">91</xref> And the overexpression of laminin would enhance gastric cancer cells’ resistance to vincristine and adriamycin via regulating MGr1-Ag/37LRP.<xref rid="CIT0092" ref-type="bibr">92</xref> This phenomenon also indicates that cell adhesion ability is associated with the chemo-resistant phenotype of gastric cancer cells, which makes it has a chance to be considered as a reference target to detect drug resistance. The mechanisms of how laminin induced drug resistance in gastric cancer are varied, including regulating the expression of multiple drug resistance-related proteins such as P-gp, and regulating apoptosis-related proteins Bcl-2 and Bax to inhibit drug-mediated apoptosis and multiple signaling pathways (PI3K/AKT and MAPK/ERK).<xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0093" ref-type="bibr">93</xref> Besides these, the high expressions of metalloproteinases inducer HMGB1 are also related to drug resistance.<xref rid="CIT0094" ref-type="bibr">94</xref>,<xref rid="CIT0095" ref-type="bibr">95</xref> Thus, there are still more details needed to be explored between the extracellular matrix and tumor drug-resistance mechanism which will bring more benefits to clinical treatment.</p></sec><sec id="S0006-S2002"><title>Cytokines and Growth Factors</title><p>The cytokines and growth factors in tumor micro-environment are involved in the activation of a variety of signaling pathways and play a key role in chemoresistance. Many cytokines and growth factors have been confirmed to act as independent factors that influence prognosis in gastric cancer patients under chemotherapy treatment.<xref rid="CIT0096" ref-type="bibr">96</xref> Interleukin family is a major part of cytokines that have been well studied. IL-6 could lead to acquired drug resistance to trastuzumab in gastric cancer cells via activation of the STAT3 signaling pathway.<xref rid="CIT0097" ref-type="bibr">97</xref> IL-33 could cause resistance to platinum through the JNK signaling pathway.<xref rid="CIT0098" ref-type="bibr">98</xref> And IL-24 has also been proved to be involved in regulating multi-drug resistance.<xref rid="CIT0099" ref-type="bibr">99</xref></p></sec><sec id="S0006-S2003"><title>Anoxia</title><p>Anoxia is an important biological characteristic in tumorigenesis and is also one of the mechanisms in drug resistance. HIF-1α is critical in cells’ response to hypoxia, and the over-expression of HIF-1α has been confirmed to be related to poor prognosis in gastric cancer in multiple studies which makes it an independent factor predicting prognosis.<xref rid="CIT0100" ref-type="bibr">100</xref>–<xref rid="CIT0102" ref-type="bibr">102</xref> Some studies have showed that HIF-1α could regulate drug resistance by regulating the expression of p53, NF-κB, Bcl-2 and serving as the down-stream target of PI3K/AKT and MAPK/ERK signaling pathways.<xref rid="CIT0103" ref-type="bibr">103</xref>–<xref rid="CIT0106" ref-type="bibr">106</xref> HIF-1α has played a significant role in inducing drug resistance in gastric cancer, while the mechanisms are still needed to be explored.<xref rid="CIT0103" ref-type="bibr">103</xref></p></sec></sec><sec id="S0007"><title>Extracellular Vesicles and Micropinocytosis</title><p>Extracellular vesicles (EVs) are secreted by nearly almost cells and released to the extracellular space. EVs could be divided into three different subgroups according to their size: exosomes (30–100 nm), micro-vesicles (MVs, 100–1000 nm), and apoptotic bodies (1000–5000 nm). While exosomes are small membrane nanovesicles which constituted through the intraluminal budding of the late endosomal membrane and are secreted from the plasma membrane.<xref rid="CIT0107" ref-type="bibr">107</xref>–<xref rid="CIT0109" ref-type="bibr">109</xref> Recently, the finding that paclitaxel-resistant gastric cancer cell line (MGC-803R) cell-derived exosomes could be taken up by paclitaxel-sensitive MGC-803 (MGC-803S) cells has been reported. Furthermore, the exosomal miR-155-5p from MGC-803R cells can join in directly inhibiting GATA binding protein 3 (GATA3) and tumor protein p53-inducible nuclear protein 1 (TP53INP1) to induce chemoresistant phenotypes in the sensitive cells which uptake the exosomes.<xref rid="CIT0110" ref-type="bibr">110</xref>,<xref rid="CIT0111" ref-type="bibr">111</xref> In addition, exosomal miR-21 can be directly transferred from macrophages to gastric cancer cells to obtain the chemotherapy resistance, and inhibit cell apoptosis and activate the PI3K/AKT pathway by regulating PTEN.<xref rid="CIT0112" ref-type="bibr">112</xref></p><p>Macropinocytosis has been known as a primary method for the cellular intake of fluid-phase and membrane-bound bulk cargo. And recent researches show that direct roles for macropinocytosis within tumorigenesis.<xref rid="CIT0113" ref-type="bibr">113</xref> Uptake of nutrients in the tumor microenvironment by macropinocytosis has recently been named as an emerging hallmark of cancer metabolism.<xref rid="CIT0114" ref-type="bibr">114</xref>,<xref rid="CIT0115" ref-type="bibr">115</xref> In lung cancer cell line A549, it has been demonstrated the extracellular ATP was internalized by macropinocytosis and induced intracellular ATP increase and drug resistance.<xref rid="CIT0116" ref-type="bibr">116</xref> In addition, there are several researches associated with macropinocytosis and drug resistance in pancreatic cancer and breast cancer.<xref rid="CIT0117" ref-type="bibr">117</xref>,<xref rid="CIT0118" ref-type="bibr">118</xref> The mechanisms and effects of micropinocytosis in gastric cancer need further study, and it may lead to a new way to solve the multi-drug resistance in gastric cancer.</p></sec><sec id="S0008"><title>MicroRNAs and LncRNAs in Drug Resistance in Gastric Cancer</title><p>With the development of research in drug resistance, new research objects are introduced into this study. MicroRNAs are noncoding single-stranded RNA molecules which contain 18 to 22 nucleotides encoded by endogenous genes. They are involved in regulating gene expression and have extensive application prospects in tumor researches,<xref rid="CIT0119" ref-type="bibr">119</xref> while lncRNAs refer to nucleotides long-chain non-coding RNA which have more than 200 nucleotides. And recent studies reveal that they are involved in cell cycle regulation, epigenetic regulation and many other aspects which make them become a focus of current researches. LncRNAs also play an important role in tumorigenesis and might be the breakthrough point.<xref rid="CIT0120" ref-type="bibr">120</xref>,<xref rid="CIT0121" ref-type="bibr">121</xref> Now, we will, respectively, introduce the two types of molecules in the research of gastric cancer’s drug-resistance briefly.</p><sec id="S0008-S2001"><title>MicroRNAs in Drug Resistance of Gastric Cancer</title><p>MicroRNAs have been extensively studied in recent years; their important roles in numerous biological behaviors begin to be revealed. A growing number of studies prove that microRNAs are significant in regulating drug transporters, transcription factors and nuclear receptors which may lead us to a new approach in drug-resistant treatment.<xref rid="CIT0122" ref-type="bibr">122</xref> In the study of the drug resistance in gastric cancer, microRNAs are also involved in several classic signaling pathways.</p><p>Bcl-2-related apoptosis pathway is important in regulating drug resistance in gastric cancer, and the current researches have shown that a variety of microRNAs are involved in regulating this pathway. MiR-503 and miR-143 can regulate the expression of IGF1R and Bcl-2 to mediate gastric cancer cells’ resistance to cisplatin.<xref rid="CIT0123" ref-type="bibr">123</xref>,<xref rid="CIT0124" ref-type="bibr">124</xref> The study of miR-200 BC/429 finds that high expression of miR-200 BC/429 will strengthen sensitivity of SGC7901/vincristine (VCR) cell line to cisplatin (CDDP), etoposide (VP-16) and adriamycin (ADR), while it is not suitable for 5-fluorouracil. And when these cells were transfected with miR-200 BC/429 inhibitor, their resistance to cisplatin, etoposide and adriamycin was enhanced. Through the luciferase assay, the Bcl-2 3ʹ-UTR reporters were detected in resistant SGC7901 cells which suggested that Bcl-2 was a target gene of the miR-200bc/429 cluster.<xref rid="CIT0125" ref-type="bibr">125</xref></p><p>PI3K/AKT signaling pathway is another important signaling pathway in drug-resistance mechanisms, while microRNAs are also involved in it. MiR-21 is detected highly expressed in SGC7901/cisplatin (CDDP) resistant cell line. Further experiments confirm that when the cells are induced with over-expression of miR-21, cell apoptosis caused by cisplatin injury would significantly reduce. On the other hand, decreasing the expression of miR-21 increases the anti-proliferative effects and CDDP-related apoptosis. It is also been found that miR-21 regulates cisplatin resistance via down-regulating the expression of PTEN and activation of the PI3K/AKT signaling pathway. This also provides us with a new method in handling the cisplatin resistance in gastric cancer via PI3K/PTEN/AKT pathway.<xref rid="CIT0126" ref-type="bibr">126</xref> Besides, miR-21 could also regulate trastuzumab’s efficiency in addition to chemotherapy in patients with HER2-positive gastric cancer. Over-expressed miR-21 would inhibit gastric cancer cell apoptosis caused by the drugs while inhibiting its expression would help with the therapy.<xref rid="CIT0127" ref-type="bibr">127</xref>,<xref rid="CIT0128" ref-type="bibr">128</xref> This result would make microRNAs an important aid in individualized medicine.</p><p>For microRNAs involve in a wide variety of drug-resistance mechanism in gastric cancer, further researches are required to conduct.<xref rid="CIT0129" ref-type="bibr">129</xref>,<xref rid="CIT0130" ref-type="bibr">130</xref> Although there is a long road for microRNAs from being applied to the treatment, they still introduce us with a new way for our future cancer treatment. New treatments based on microRNAs will come out in the near future promisingly.</p></sec><sec id="S0008-S2002"><title>LncRNAs in Drug Resistance of Gastric Cancer</title><p>In the study of gastric cancer, a variety of abnormal-expressed lncRNAs have been proved to be critical in tumorigenesis, metastasis and drug resistance. PVT1, a lncRNA which is associated with gastric cancer, is closely related with the development and MDR in gastric cancer. Recent researches show that PVT-1 is highly expressed in gastric cancer tissues of cisplatin-resistant patients and SGC7901/DDP cells. In addition, PVT1 is also a risk factor in lymph nodes metastasis. These features make PVT1 have the potential to be the new biomarkers for the evaluation of patients with gastric cancer.<xref rid="CIT0131" ref-type="bibr">131</xref>,<xref rid="CIT0132" ref-type="bibr">132</xref> And in the prescription of drug resistance in gastric cancer, up-regulating PVT1’s expression would raise the expression of p-glycoprotein, MRP, mTOR and HIF-1α to induce multidrug-resistance, while inhibiting PVT1’s expression would reverse cell resistance to cisplatin.<xref rid="CIT0133" ref-type="bibr">133</xref>,<xref rid="CIT0134" ref-type="bibr">134</xref> Other studies have shown that down-regulating the expression of LEIGC in gastric cancer cells could enhance the resistance to 5-fluorouracil via regulating the EMT process, which suggested LEIGC could be a suppressor lncRNA in gastric cancer.<xref rid="CIT0135" ref-type="bibr">135</xref> Further studies have found that the target site of lncRNA MRUL is close to p-glycoprotein, and the expression of MRUL is higher in drug-resistance cells. For p-glycoprotein is one of the important proteins in inducing multidrug resistance, patients with high expression of MRUL show poor reactivity of chemotherapy drugs in clinical practice. And another study reveals that MRUL induces resistance to adriamycin by regulating the expression of ABCB1 in gastric cancer.<xref rid="CIT0136" ref-type="bibr">136</xref></p><p>New lncRNAs are also added to some common molecular mechanism and signaling pathway due to the recent studies, such as Notch 1 could increase lncRNA AK022798 expression to induce resistance to cisplatin in gastric cancer.<xref rid="CIT0137" ref-type="bibr">137</xref> LncRNA HOTAIR could also activate the PI3K/AKT pathway and regulate the expression of p-glycoprotein through miR-216.<xref rid="CIT0138" ref-type="bibr">138</xref> On the other hand, the connection between lncRNAs and microRNAs has been revealed, such as lncRNA UCA1 could enhance drug resistance by down-regulating miR-27b.<xref rid="CIT0139" ref-type="bibr">139</xref> With the deepening of the researches, lncRNAs could play a more active role in gastric cancer drug-resistance treatment.</p></sec></sec><sec id="S0009"><title>Discussion</title><p>The preferred treatment for advanced-stage gastric cancer is still surgical operation.<xref rid="CIT0140" ref-type="bibr">140</xref>,<xref rid="CIT0141" ref-type="bibr">141</xref> However, for patients who have no chance to get surgical treatment, the ultimate goal of comprehensive treatment is to prolong survival and improve the quality of life. The development and progress of novel chemotherapy, targeted drugs, immunotherapy will provide new opportunities for the comprehensive treatment of gastric cancer. We could bring better clinical benefit to patients by carrying out a more comprehensive and personalized diagnosis and treatment strategy. Meanwhile, drug resistance is still one of the major obstacles in gastric cancer treatments. Although there are many mechanisms that have been revealed above, the clinical application is still limited.</p><p>The networks of drug-resistance-related pathways are complicated, and many proteins and molecules are involved (<xref rid="F0001" ref-type="fig">Figure 1</xref>). It might be hard to distinguish them apart. But the main goal of improving the therapy by enhancing the efficiency of the drugs is similar.<fig id="F0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The summary of mechanisms of drug resistance in gastric cancer.</p></caption><graphic content-type="print-only" xlink:href="OTT-13-1797-g0001"></graphic></fig></p><p>As we have discussed above, the regulation of certain miRNA or lncRNA expressions could participate in improving the response of GC cell lines to chemotherapy and significantly enhance the antitumor properties of specific drugs. It could be helpful in developing personalized therapies, as well as establishing novel therapeutic strategies to reverse the resistance of tumors in combination with chemotherapeutic agents. And macropinocytosis could be used as a new target for therapy and might help with transfer the drug into the cells. Despite these hypotheses, there are many other ways we could try in this field.</p><p>In conclusion, there are more studies have been carried out to reveal the mechanisms of drug resistance in gastric cancer, the related pathways and molecules above are likely to help us solve this problem in future. For drug resistance is caused by multiple factors, it makes our research more complicated and brings a challenge in clinical application. However, we should believe that with the development of our technology, the situation will be improved and the patients will get benefit.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by grants from NSFC to Chuanqing Wu (grant 81600401), Hubei Provincial Natural Science Foundation of China to Chuanqing Wu (grant 2017CFB474), and Health Commission of Hubei Province to Chuanqing Wu (grant WJ2019Q035).</p></ack><sec id="S0010" sec-type="COI-statement"><title>Disclosure</title><p>The authors declare no competing interests.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Torre</surname><given-names>LA</given-names></string-name>, <string-name><surname>Bray</surname><given-names>F</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name><surname>Lortet-Tieulent</surname><given-names>J</given-names></string-name>, <string-name><surname>Jemal</surname><given-names>A</given-names></string-name>. <article-title>Global cancer statistics, 2012</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2015</year>;<volume>65</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>108</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><pub-id pub-id-type="pmid">25651787</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>R</given-names></string-name>, <string-name><surname>Baade</surname><given-names>PD</given-names></string-name>, et al. <article-title>Cancer statistics in China, 2015</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2016</year>;<volume>66</volume>(<issue>2</issue>):<fpage>115</fpage>–<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21338</pub-id><pub-id pub-id-type="pmid">26808342</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X-J</given-names></string-name>, <string-name><surname>Gao</surname><given-names>R</given-names></string-name>. <article-title>Research Advances in the Mechanisms of Gastric Cancer Multidrug Resistance</article-title>. <source><italic toggle="yes">Zhongguo Yi Xue Ke Xue Yuan Xue Bao</italic></source>. <year>2016</year>;<volume>38</volume>(<issue>6</issue>):<fpage>739</fpage>–<lpage>745</lpage>. doi:<pub-id pub-id-type="doi">10.3881/j.issn.1000-503X.2016.06.020</pub-id><pub-id pub-id-type="pmid">28065245</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Cunningham</surname><given-names>D</given-names></string-name>, <string-name><surname>Allum</surname><given-names>WH</given-names></string-name>, <string-name><surname>Stenning</surname><given-names>SP</given-names></string-name>, et al. <article-title>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2006</year>;<volume>355</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa055531</pub-id><pub-id pub-id-type="pmid">16822992</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Catalano</surname><given-names>V</given-names></string-name>, <string-name><surname>Labianca</surname><given-names>R</given-names></string-name>, <string-name><surname>Beretta</surname><given-names>GD</given-names></string-name>, <string-name><surname>Gatta</surname><given-names>G</given-names></string-name>, <string-name><surname>de Braud</surname><given-names>F</given-names></string-name>, <string-name><surname>Van Cutsem</surname><given-names>E</given-names></string-name>. <article-title>Gastric cancer</article-title>. <source><italic toggle="yes">Crit Rev Oncol Hematol</italic></source>. <year>2009</year>;<volume>71</volume>(<issue>2</issue>):<fpage>127</fpage>–<lpage>164</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.critrevonc.2009.01.004</pub-id><pub-id pub-id-type="pmid">19230702</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Lippert</surname><given-names>TH</given-names></string-name>, <string-name><surname>Ruoff</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Volm</surname><given-names>M</given-names></string-name>. <article-title>Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure</article-title>. <source><italic toggle="yes">Arzneimittelforschung</italic></source>. <year>2008</year>;<volume>58</volume>(<issue>6</issue>):<fpage>261</fpage>–<lpage>264</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0031-1296504</pub-id><pub-id pub-id-type="pmid">18677966</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Wagner</surname><given-names>AD</given-names></string-name>, <string-name><surname>Grothe</surname><given-names>W</given-names></string-name>, <string-name><surname>Haerting</surname><given-names>J</given-names></string-name>, <string-name><surname>Kleber</surname><given-names>G</given-names></string-name>, <string-name><surname>Grothey</surname><given-names>A</given-names></string-name>, <string-name><surname>Fleig</surname><given-names>WE</given-names></string-name>. <article-title>Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2006</year>;<volume>24</volume>(<issue>18</issue>):<fpage>2903</fpage>–<lpage>2909</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2005.05.0245</pub-id><pub-id pub-id-type="pmid">16782930</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>XQ</given-names></string-name>, <string-name><surname>Ren</surname><given-names>XG</given-names></string-name>. <article-title>Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis</article-title>. <source><italic toggle="yes">Medicine</italic></source>. <year>2017</year>;<volume>96</volume>(<issue>24</issue>):<fpage>e6884</fpage>. doi:<pub-id pub-id-type="doi">10.1097/MD.0000000000006884</pub-id><pub-id pub-id-type="pmid">28614219</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Szakacs</surname><given-names>G</given-names></string-name>, <string-name><surname>Jakab</surname><given-names>K</given-names></string-name>, <string-name><surname>Antal</surname><given-names>F</given-names></string-name>, <string-name><surname>Sarkadi</surname><given-names>B</given-names></string-name>. <article-title>Diagnostics of multidrug resistance in cancer</article-title>. <source><italic toggle="yes">Pathol Oncol Res</italic></source>. <year>1998</year>;<volume>4</volume>(<issue>4</issue>):<fpage>251</fpage>–<lpage>257</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF02905214</pub-id><pub-id pub-id-type="pmid">9887354</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Volm</surname><given-names>M</given-names></string-name>, <string-name><surname>Efferth</surname><given-names>T</given-names></string-name>. <article-title>Prediction of cancer drug resistance and implications for personalized medicine</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2015</year>;<volume>5</volume>:<fpage>282</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2015.00282</pub-id><pub-id pub-id-type="pmid">26734568</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Bunting</surname><given-names>KD</given-names></string-name>. <article-title>ABC transporters as phenotypic markers and functional regulators of stem cells</article-title>. <source><italic toggle="yes">Stem Cells</italic></source>. <year>2002</year>;<volume>20</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1002/stem.200011</pub-id><pub-id pub-id-type="pmid">11796918</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Choi</surname><given-names>YH</given-names></string-name>, <string-name><surname>Yu</surname><given-names>AM</given-names></string-name>. <article-title>ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development</article-title>. <source><italic toggle="yes">Curr Pharm Des</italic></source>. <year>2014</year>;<volume>20</volume>(<issue>5</issue>):<fpage>793</fpage>–<lpage>807</lpage>. doi:<pub-id pub-id-type="doi">10.2174/138161282005140214165212</pub-id><pub-id pub-id-type="pmid">23688078</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Cui</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name><surname>Liu</surname><given-names>JJ</given-names></string-name>. <article-title>ABC transporter inhibitors in reversing multidrug resistance to chemotherapy</article-title>. <source><italic toggle="yes">Curr Drug Targets</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>12</issue>):<fpage>1356</fpage>–<lpage>1371</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1389450116666150330113506</pub-id><pub-id pub-id-type="pmid">25901528</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Iangcharoen</surname><given-names>P</given-names></string-name>, <string-name><surname>Punfa</surname><given-names>W</given-names></string-name>, <string-name><surname>Yodkeeree</surname><given-names>S</given-names></string-name>, et al. <article-title>Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment</article-title>. <source><italic toggle="yes">Arch Pharm Res</italic></source>. <year>2011</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1679</fpage>–<lpage>1689</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12272-011-1012-4</pub-id><pub-id pub-id-type="pmid">22076768</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, et al. <article-title>Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells</article-title>. <source><italic toggle="yes">Molecules</italic></source>. <year>2013</year>;<volume>19</volume>(<issue>1</issue>):<fpage>159</fpage>–<lpage>176</lpage>. doi:<pub-id pub-id-type="doi">10.3390/molecules19010159</pub-id><pub-id pub-id-type="pmid">24368600</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Monden</surname><given-names>N</given-names></string-name>, <string-name><surname>Abe</surname><given-names>S</given-names></string-name>, <string-name><surname>Hishikawa</surname><given-names>Y</given-names></string-name>, et al. <article-title>The role of P-glycoprotein in human gastric cancer xenografts in response to chemotherapy</article-title>. <source><italic toggle="yes">Int J Surg Investig</italic></source>. <year>1999</year>;<volume>1</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>10</lpage>.</mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Rocco</surname><given-names>A</given-names></string-name>, <string-name><surname>Compare</surname><given-names>D</given-names></string-name>, <string-name><surname>Liguori</surname><given-names>E</given-names></string-name>, et al. <article-title>MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells</article-title>. <source><italic toggle="yes">Lab Invest</italic></source>. <year>2012</year>;<volume>92</volume>(<issue>10</issue>):<fpage>1407</fpage>–<lpage>1418</lpage>. doi:<pub-id pub-id-type="doi">10.1038/labinvest.2012.100</pub-id><pub-id pub-id-type="pmid">22751348</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>de Oliveira</surname><given-names>J</given-names></string-name>, <string-name><surname>Felipe</surname><given-names>AV</given-names></string-name>, <string-name><surname>Neto</surname><given-names>RA</given-names></string-name>, <string-name><surname>Oshima</surname><given-names>CT</given-names></string-name>, <string-name><surname>de Souza Silva</surname><given-names>M</given-names></string-name>, <string-name><surname>Forones</surname><given-names>NM</given-names></string-name>. <article-title>Association between ABCB1 immunohistochemical expression and overall survival in gastric cancer patients</article-title>. <source><italic toggle="yes">Asian Pac J Cancer Prev</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>16</issue>):<fpage>6935</fpage>–<lpage>6938</lpage>. doi:<pub-id pub-id-type="doi">10.7314/APJCP.2014.15.16.6935</pub-id><pub-id pub-id-type="pmid">25169549</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Chung</surname><given-names>HC</given-names></string-name>, <string-name><surname>Gong</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Yoo</surname><given-names>NC</given-names></string-name>, et al. <article-title>P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer</article-title>. <source><italic toggle="yes">Yonsei Med J</italic></source>. <year>1996</year>;<volume>37</volume>(<issue>6</issue>):<fpage>397</fpage>–<lpage>404</lpage>. doi:<pub-id pub-id-type="doi">10.3349/ymj.1996.37.6.397</pub-id><pub-id pub-id-type="pmid">9048492</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Katayama</surname><given-names>K</given-names></string-name>, <string-name><surname>Yoshioka</surname><given-names>S</given-names></string-name>, <string-name><surname>Tsukahara</surname><given-names>S</given-names></string-name>, <string-name><surname>Mitsuhashi</surname><given-names>J</given-names></string-name>, <string-name><surname>Sugimoto</surname><given-names>Y</given-names></string-name>. <article-title>Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2007</year>;<volume>6</volume>(<issue>7</issue>):<fpage>2092</fpage>–<lpage>2102</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0148</pub-id><pub-id pub-id-type="pmid">17620438</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Bentires-Alj</surname><given-names>M</given-names></string-name>, <string-name><surname>Barbu</surname><given-names>V</given-names></string-name>, <string-name><surname>Fillet</surname><given-names>M</given-names></string-name>, et al. <article-title>NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells</article-title>. <source><italic toggle="yes">Oncogene</italic></source>. <year>2003</year>;<volume>22</volume>(<issue>1</issue>):<fpage>90</fpage>–<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.onc.1206056</pub-id><pub-id pub-id-type="pmid">12527911</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname><given-names>ZA</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>ZQ</given-names></string-name>, <string-name><surname>Cai</surname><given-names>HX</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>. <article-title>Reversion of multidrug resistance by SKI-II in SGC7901/DDP cells and exploration of underlying mechanisms</article-title>. <source><italic toggle="yes">Asian Pac J Cancer Prev</italic></source>. <year>2012</year>;<volume>13</volume>(<issue>2</issue>):<fpage>625</fpage>–<lpage>631</lpage>. doi:<pub-id pub-id-type="doi">10.7314/APJCP.2012.13.2.625</pub-id><pub-id pub-id-type="pmid">22524836</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Mao</surname><given-names>Z</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name><surname>Luan</surname><given-names>J</given-names></string-name>, <string-name><surname>Sheng</surname><given-names>W</given-names></string-name>, <string-name><surname>Shen</surname><given-names>X</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X</given-names></string-name>. <article-title>Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells</article-title>. <source><italic toggle="yes">Biomed Pharmacother</italic></source>. <year>2014</year>;<volume>68</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>183</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2013.10.003</pub-id><pub-id pub-id-type="pmid">24184201</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Han</surname><given-names>Z</given-names></string-name>, <string-name><surname>Hong</surname><given-names>L</given-names></string-name>, <string-name><surname>Han</surname><given-names>Y</given-names></string-name>, et al. <article-title>Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2007</year>;<volume>26</volume>(<issue>2</issue>):<fpage>261</fpage>–<lpage>268</lpage>.<pub-id pub-id-type="pmid">17725107</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name><surname>Tang</surname><given-names>B</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>P</given-names></string-name>. <article-title>Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2013</year>;<volume>30</volume>(<issue>2</issue>):<fpage>773</fpage>–<lpage>782</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2013.2520</pub-id><pub-id pub-id-type="pmid">23743572</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Schecter</surname><given-names>RL</given-names></string-name>, <string-name><surname>Alaoui-Jamali</surname><given-names>MA</given-names></string-name>, <string-name><surname>Batist</surname><given-names>G</given-names></string-name>. <article-title>Glutathione S-transferase in chemotherapy resistance and in carcinogenesis</article-title>. <source><italic toggle="yes">Biochem Cell Biol</italic></source>. <year>1992</year>;<volume>70</volume>(<issue>5</issue>):<fpage>349</fpage>–<lpage>353</lpage>. doi:<pub-id pub-id-type="doi">10.1139/o92-054</pub-id><pub-id pub-id-type="pmid">1353967</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Lo</surname><given-names>HW</given-names></string-name>, <string-name><surname>Ali-Osman</surname><given-names>F</given-names></string-name>. <article-title>Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance</article-title>. <source><italic toggle="yes">Curr Opin Pharmacol</italic></source>. <year>2007</year>;<volume>7</volume>(<issue>4</issue>):<fpage>367</fpage>–<lpage>374</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.coph.2007.06.009</pub-id><pub-id pub-id-type="pmid">17681492</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Peters</surname><given-names>WH</given-names></string-name>, <string-name><surname>Wormskamp</surname><given-names>NG</given-names></string-name>, <string-name><surname>Thies</surname><given-names>E</given-names></string-name>. <article-title>Expression of glutathione S-transferases in normal gastric mucosa and in gastric tumors</article-title>. <source><italic toggle="yes">Carcinogenesis</italic></source>. <year>1990</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1593</fpage>–<lpage>1596</lpage>. doi:<pub-id pub-id-type="doi">10.1093/carcin/11.9.1593</pub-id><pub-id pub-id-type="pmid">2401049</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Kodera</surname><given-names>Y</given-names></string-name>, <string-name><surname>Isobe</surname><given-names>K</given-names></string-name>, <string-name><surname>Yamauchi</surname><given-names>M</given-names></string-name>, et al. <article-title>Expression of glutathione-S-transferases alpha and pi in gastric cancer: a correlation with cisplatin resistance</article-title>. <source><italic toggle="yes">Cancer Chemother Pharmacol</italic></source>. <year>1994</year>;<volume>34</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>208</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF00685078</pub-id><pub-id pub-id-type="pmid">8004752</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Schipper</surname><given-names>DL</given-names></string-name>, <string-name><surname>Wagenmans</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Peters</surname><given-names>WH</given-names></string-name>, <string-name><surname>Wils</surname><given-names>JA</given-names></string-name>, <string-name><surname>Wagener</surname><given-names>DJ</given-names></string-name>. <article-title>Glutathione S-transferases and iododeoxyuridine labelling index during chemotherapy of gastric cancer</article-title>. <source><italic toggle="yes">Anticancer Res</italic></source>. <year>2000</year>;<volume>20</volume>(<issue>3a</issue>):<fpage>1705</fpage>–<lpage>1710</lpage>.<pub-id pub-id-type="pmid">10928096</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname><given-names>R</given-names></string-name>, <string-name><surname>Ohi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Inoue</surname><given-names>H</given-names></string-name>, <string-name><surname>Toge</surname><given-names>T</given-names></string-name>. <article-title>Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers</article-title>. <source><italic toggle="yes">Anticancer Res</italic></source>. <year>1999</year>;<volume>19</volume>(<issue>6b</issue>):<fpage>5393</fpage>–<lpage>5398</lpage>.<pub-id pub-id-type="pmid">10697567</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name><surname>Gao</surname><given-names>J</given-names></string-name>, et al. <article-title>Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications</article-title>. <source><italic toggle="yes">Cancer Genomics Proteomics</italic></source>. <year>2011</year>;<volume>8</volume>(<issue>3</issue>):<fpage>127</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="pmid">21518818</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>P</given-names></string-name>, <string-name><surname>Du</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L</given-names></string-name>, <string-name><surname>Fan</surname><given-names>S</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>S</given-names></string-name>. <article-title>Significance of multidrug resistance gene-related proteins in the postoperative chemotherapy of gastric cancer</article-title>. <source><italic toggle="yes">Int J Clin Exp Pathol</italic></source>. <year>2014</year>;<volume>7</volume>(<issue>11</issue>):<fpage>7945</fpage>–<lpage>7950</lpage>.<pub-id pub-id-type="pmid">25550836</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Geng</surname><given-names>M</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Cao</surname><given-names>R</given-names></string-name>, <string-name><surname>Li</surname><given-names>P</given-names></string-name>. <article-title>The association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancer</article-title>. <source><italic toggle="yes">Diagn Pathol</italic></source>. <year>2013</year>;<volume>8</volume>:<fpage>198</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1746-1596-8-198</pub-id><pub-id pub-id-type="pmid">24326092</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Son</surname><given-names>YS</given-names></string-name>, <string-name><surname>Suh</surname><given-names>JM</given-names></string-name>, <string-name><surname>Ahn</surname><given-names>SH</given-names></string-name>, et al. <article-title>Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line</article-title>. <source><italic toggle="yes">Cancer Chemother Pharmacol</italic></source>. <year>1998</year>;<volume>41</volume>(<issue>5</issue>):<fpage>353</fpage>–<lpage>360</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s002800050751</pub-id><pub-id pub-id-type="pmid">9523730</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Zugazagoitia</surname><given-names>J</given-names></string-name>, <string-name><surname>Guedes</surname><given-names>C</given-names></string-name>, <string-name><surname>Ponce</surname><given-names>S</given-names></string-name>, <string-name><surname>Ferrer</surname><given-names>I</given-names></string-name>, <string-name><surname>Molina-Pinelo</surname><given-names>S</given-names></string-name>, <string-name><surname>Paz-Ares</surname><given-names>L</given-names></string-name>. <article-title>Current challenges in cancer treatment</article-title>. <source><italic toggle="yes">Clin Ther</italic></source>. <year>2016</year>;<volume>38</volume>(<issue>7</issue>):<fpage>1551</fpage>–<lpage>1566</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2016.03.026</pub-id><pub-id pub-id-type="pmid">27158009</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname><given-names>W</given-names></string-name>, <string-name><surname>Raufi</surname><given-names>A</given-names></string-name>, <string-name><surname>Klempner</surname><given-names>SJ</given-names></string-name>. <article-title>Targeted therapy for gastric cancer: molecular pathways and ongoing investigations</article-title>. <source><italic toggle="yes">Biochim Biophys Acta</italic></source>. <year>2014</year>;<volume>1846</volume>(<issue>1</issue>):<fpage>232</fpage>–<lpage>237</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbcan.2014.05.003</pub-id><pub-id pub-id-type="pmid">24858418</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name><surname>Huang</surname><given-names>KE</given-names></string-name>, <string-name><surname>Pan</surname><given-names>YL</given-names></string-name>, et al. <article-title>KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance</article-title>. <source><italic toggle="yes">Gastric Cancer</italic></source>. <year>2015</year>;<volume>18</volume>(<issue>4</issue>):<fpage>796</fpage>–<lpage>802</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10120-014-0414-7</pub-id><pub-id pub-id-type="pmid">25182956</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Serrano</surname><given-names>C</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Marino-Enriquez</surname><given-names>A</given-names></string-name>, et al. <article-title>KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in gi stromal tumors: relevance of concomitant phosphatidylinositol 3-kinase/AKT dysregulation</article-title>. <source><italic toggle="yes">J Clin Oncol</italic></source>. <year>2015</year>;<volume>33</volume>(<issue>22</issue>):<fpage>e93</fpage>–<lpage>e96</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2013.48.7488</pub-id><pub-id pub-id-type="pmid">24687822</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Sanchez-Olea</surname><given-names>R</given-names></string-name>, <string-name><surname>Calera</surname><given-names>MR</given-names></string-name>, <string-name><surname>Degterev</surname><given-names>A</given-names></string-name>. <article-title>Molecular pathways involved in cell death after chemically induced DNA damage</article-title>. <source><italic toggle="yes">Exs</italic></source>. <year>2009</year>;<volume>99</volume>:<fpage>209</fpage>–<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.1007/978-3-7643-8336-7_8</pub-id><pub-id pub-id-type="pmid">19157063</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Boland</surname><given-names>CR</given-names></string-name>. <article-title>Roles of the DNA mismatch repair genes in colorectal tumorigenesis</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>1996</year>;<volume>69</volume>(<issue>1</issue>):<fpage>47</fpage>–<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(ISSN)1097-0215</pub-id><pub-id pub-id-type="pmid">8600059</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname><given-names>CT</given-names></string-name>, <string-name><surname>Lyu</surname><given-names>YL</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>H</given-names></string-name>, <string-name><surname>Lin</surname><given-names>WH</given-names></string-name>, <string-name><surname>Whang-Peng</surname><given-names>J</given-names></string-name>. <article-title>Suppression of gene amplification and chromosomal DNA integration by the DNA mismatch repair system</article-title>. <source><italic toggle="yes">Nucleic Acids Res</italic></source>. <year>2001</year>;<volume>29</volume>(<issue>16</issue>):<fpage>3304</fpage>–<lpage>3310</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/29.16.3304</pub-id><pub-id pub-id-type="pmid">11504867</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Tanida</surname><given-names>S</given-names></string-name>, <string-name><surname>Mizoshita</surname><given-names>T</given-names></string-name>, <string-name><surname>Ozeki</surname><given-names>K</given-names></string-name>, et al. <article-title>Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment</article-title>. <source><italic toggle="yes">Int J Surg Oncol</italic></source>. <year>2012</year>;<volume>2012</volume>:<fpage>862879</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2012/862879</pub-id><pub-id pub-id-type="pmid">22778941</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Marteijn</surname><given-names>JA</given-names></string-name>, <string-name><surname>Lans</surname><given-names>H</given-names></string-name>, <string-name><surname>Vermeulen</surname><given-names>W</given-names></string-name>, <string-name><surname>Hoeijmakers</surname><given-names>JH</given-names></string-name>. <article-title>Understanding nucleotide excision repair and its roles in cancer and ageing</article-title>. <source><italic toggle="yes">Nat Rev Mol Cell Biol</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>7</issue>):<fpage>465</fpage>–<lpage>481</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrm3822</pub-id><pub-id pub-id-type="pmid">24954209</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>He</surname><given-names>C</given-names></string-name>, <string-name><surname>Xing</surname><given-names>C</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>. <article-title>Nucleotide excision repair related gene polymorphisms and genetic susceptibility, chemotherapeutic sensitivity and prognosis of gastric cancer</article-title>. <source><italic toggle="yes">Mutat Res</italic></source>. <year>2014</year>;<volume>765</volume>:<fpage>11</fpage>–<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mrfmmm.2014.04.008</pub-id><pub-id pub-id-type="pmid">24769428</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Simonelli</surname><given-names>V</given-names></string-name>, <string-name><surname>Leuzzi</surname><given-names>G</given-names></string-name>, <string-name><surname>Basile</surname><given-names>G</given-names></string-name>, et al. <article-title>Crosstalk between mismatch repair and base excision repair in human gastric cancer</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>49</issue>):<fpage>84827</fpage>–<lpage>84840</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.v8i49</pub-id><pub-id pub-id-type="pmid">29156686</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Longley</surname><given-names>DB</given-names></string-name>, <string-name><surname>Johnston</surname><given-names>PG</given-names></string-name>. <article-title>Molecular mechanisms of drug resistance</article-title>. <source><italic toggle="yes">J Pathol</italic></source>. <year>2005</year>;<volume>205</volume>(<issue>2</issue>):<fpage>275</fpage>–<lpage>292</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(ISSN)1096-9896</pub-id><pub-id pub-id-type="pmid">15641020</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name><surname>Hui</surname><given-names>KM</given-names></string-name>. <article-title>Mechanism of cancer drug resistance and the involvement of noncoding RNAs</article-title>. <source><italic toggle="yes">Curr Med Chem</italic></source>. <year>2014</year>;<volume>21</volume>(<issue>26</issue>):<fpage>3029</fpage>–<lpage>3041</lpage>. doi:<pub-id pub-id-type="doi">10.2174/0929867321666140414101939</pub-id><pub-id pub-id-type="pmid">24735364</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Geng</surname><given-names>M</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>P</given-names></string-name>. <article-title>Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer</article-title>. <source><italic toggle="yes">Int J Clin Exp Pathol</italic></source>. <year>2013</year>;<volume>6</volume>(<issue>11</issue>):<fpage>2554</fpage>–<lpage>2559</lpage>.<pub-id pub-id-type="pmid">24228120</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Cheng</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Li</surname><given-names>T</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>. <article-title>Bcl-2 expression and patient survival in gastric cancer: a systematic review of the literature with meta-analysis</article-title>. <source><italic toggle="yes">Med Oncol</italic></source>. <year>2015</year>;<volume>32</volume>(<issue>1</issue>):<fpage>389</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s12032-014-0389-6</pub-id><pub-id pub-id-type="pmid">25428392</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>DF</given-names></string-name>, <string-name><surname>Wu</surname><given-names>FR</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Xia</surname><given-names>Q</given-names></string-name>. <article-title>Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells</article-title>. <source><italic toggle="yes">Biomed Pharmacother</italic></source>. <year>2013</year>;<volume>67</volume>(<issue>7</issue>):<fpage>615</fpage>–<lpage>619</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2013.03.007</pub-id><pub-id pub-id-type="pmid">23684481</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Jeong</surname><given-names>SH</given-names></string-name>, <string-name><surname>Han</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JH</given-names></string-name>, et al. <article-title>Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy</article-title>. <source><italic toggle="yes">Dig Dis Sci</italic></source>. <year>2011</year>;<volume>56</volume>(<issue>1</issue>):<fpage>131</fpage>–<lpage>138</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10620-010-1280-8</pub-id><pub-id pub-id-type="pmid">20503071</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Sawa</surname><given-names>H</given-names></string-name>, <string-name><surname>Kobayashi</surname><given-names>T</given-names></string-name>, <string-name><surname>Mukai</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name><surname>Shiku</surname><given-names>H</given-names></string-name>. <article-title>Bax overexpression enhances cytochrome c release from mitochondria and sensitizes KATOIII gastric cancer cells to chemotherapeutic agent-induced apoptosis</article-title>. <source><italic toggle="yes">Int J Oncol</italic></source>. <year>2000</year>;<volume>16</volume>(<issue>4</issue>):<fpage>745</fpage>–<lpage>749</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ijo.16.4.745</pub-id><pub-id pub-id-type="pmid">10717243</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Tahara</surname><given-names>M</given-names></string-name>, <string-name><surname>Ochiai</surname><given-names>A</given-names></string-name>, <string-name><surname>Fujimoto</surname><given-names>J</given-names></string-name>, et al. <article-title>Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2004</year>;<volume>11</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">14654896</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Tsujitani</surname><given-names>S</given-names></string-name>, <string-name><surname>Saito</surname><given-names>H</given-names></string-name>, <string-name><surname>Wakatsuki</surname><given-names>T</given-names></string-name>, et al. <article-title>Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer</article-title>. <source><italic toggle="yes">Surg Today</italic></source>. <year>2012</year>;<volume>42</volume>(<issue>3</issue>):<fpage>225</fpage>–<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00595-011-0062-z</pub-id><pub-id pub-id-type="pmid">22143356</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Villamizar</surname><given-names>O</given-names></string-name>, <string-name><surname>Chambers</surname><given-names>CB</given-names></string-name>, <string-name><surname>Riberdy</surname><given-names>JM</given-names></string-name>, <string-name><surname>Persons</surname><given-names>DA</given-names></string-name>, <string-name><surname>Wilber</surname><given-names>A</given-names></string-name>. <article-title>Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>12</issue>):<fpage>13810</fpage>–<lpage>13826</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.v7i12</pub-id><pub-id pub-id-type="pmid">26885613</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Rippa</surname><given-names>E</given-names></string-name>, <string-name><surname>La Monica</surname><given-names>G</given-names></string-name>, <string-name><surname>Allocca</surname><given-names>R</given-names></string-name>, <string-name><surname>Romano</surname><given-names>MF</given-names></string-name>, <string-name><surname>De Palma</surname><given-names>M</given-names></string-name>, <string-name><surname>Arcari</surname><given-names>P</given-names></string-name>. <article-title>Overexpression of gastrokine 1 in gastric cancer cells induces Fas-mediated apoptosis</article-title>. <source><italic toggle="yes">J Cell Physiol</italic></source>. <year>2011</year>;<volume>226</volume>(<issue>10</issue>):<fpage>2571</fpage>–<lpage>2578</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.v226.10</pub-id><pub-id pub-id-type="pmid">21792914</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Souza</surname><given-names>PS</given-names></string-name>, <string-name><surname>Madigan</surname><given-names>JP</given-names></string-name>, <string-name><surname>Gillet</surname><given-names>JP</given-names></string-name>, et al. <article-title>Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL</article-title>. <source><italic toggle="yes">Exp Cell Res</italic></source>. <year>2015</year>;<volume>336</volume>(<issue>2</issue>):<fpage>318</fpage>–<lpage>328</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.yexcr.2015.06.005</pub-id><pub-id pub-id-type="pmid">26101157</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Matozaki</surname><given-names>T</given-names></string-name>, <string-name><surname>Sakamoto</surname><given-names>C</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>T</given-names></string-name>, et al. <article-title>p53 gene mutations in human gastric cancer: wild-type p53 but not mutant p53 suppresses growth of human gastric cancer cells</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>1992</year>;<volume>52</volume>(<issue>16</issue>):<fpage>4335</fpage>–<lpage>4341</lpage>.<pub-id pub-id-type="pmid">1322785</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Yildirim</surname><given-names>M</given-names></string-name>, <string-name><surname>Kaya</surname><given-names>V</given-names></string-name>, <string-name><surname>Demirpence</surname><given-names>O</given-names></string-name>, <string-name><surname>Gunduz</surname><given-names>S</given-names></string-name>, <string-name><surname>Bozcuk</surname><given-names>H</given-names></string-name>. <article-title>Prognostic significance of p53 in gastric cancer: a meta- analysis</article-title>. <source><italic toggle="yes">Asian Pac J Cancer Prev</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>327</fpage>–<lpage>332</lpage>. doi:<pub-id pub-id-type="doi">10.7314/APJCP.2015.16.1.327</pub-id><pub-id pub-id-type="pmid">25640374</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Xu</surname><given-names>HY</given-names></string-name>, <string-name><surname>Xu</surname><given-names>WL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>LQ</given-names></string-name>, <string-name><surname>Chen</surname><given-names>MB</given-names></string-name>, <string-name><surname>Shen</surname><given-names>HL</given-names></string-name>. <article-title>Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>e95371</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0095371</pub-id><pub-id pub-id-type="pmid">24740294</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>GX</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>LH</given-names></string-name>, <string-name><surname>Liu</surname><given-names>SY</given-names></string-name>, <string-name><surname>He</surname><given-names>XH</given-names></string-name>. <article-title>rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy</article-title>. <source><italic toggle="yes">World J Gastroenterol</italic></source>. <year>2011</year>;<volume>17</volume>(<issue>38</issue>):<fpage>4289</fpage>–<lpage>4297</lpage>. doi:<pub-id pub-id-type="doi">10.3748/wjg.v17.i38.4289</pub-id><pub-id pub-id-type="pmid">22090785</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname><given-names>CW</given-names></string-name>, <string-name><surname>Lu</surname><given-names>JN</given-names></string-name>, <string-name><surname>Go</surname><given-names>SI</given-names></string-name>, et al. <article-title>p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax</article-title>. <source><italic toggle="yes">Int J Oncol</italic></source>. <year>2013</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1495</fpage>–<lpage>1502</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ijo.2013.2070</pub-id><pub-id pub-id-type="pmid">23970333</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Tang</surname><given-names>L</given-names></string-name>, <string-name><surname>Long</surname><given-names>Z</given-names></string-name>, <string-name><surname>Feng</surname><given-names>G</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name><surname>Yu</surname><given-names>M</given-names></string-name>. <article-title>NES1/KLK10 promotes trastuzumab resistance via activation of PI3K/AKT signaling pathway in gastric cancer</article-title>. <source><italic toggle="yes">J Cell Biochem</italic></source>. <year>2017</year>.</mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Liang</surname><given-names>J</given-names></string-name>, <string-name><surname>Ge</surname><given-names>F</given-names></string-name>, <string-name><surname>Guo</surname><given-names>C</given-names></string-name>, et al. <article-title>Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells</article-title>. <source><italic toggle="yes">FEBS J</italic></source>. <year>2009</year>;<volume>276</volume>(<issue>3</issue>):<fpage>685</fpage>–<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06816.x</pub-id><pub-id pub-id-type="pmid">19143835</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname><given-names>SQ</given-names></string-name>, <string-name><surname>Yu</surname><given-names>JP</given-names></string-name>, <string-name><surname>Yu</surname><given-names>HG</given-names></string-name>, <string-name><surname>Lv</surname><given-names>P</given-names></string-name>, <string-name><surname>Chen</surname><given-names>HL</given-names></string-name>. <article-title>Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells</article-title>. <source><italic toggle="yes">Dig Liver Dis</italic></source>. <year>2006</year>;<volume>38</volume>(<issue>5</issue>):<fpage>310</fpage>–<lpage>318</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dld.2006.01.012</pub-id><pub-id pub-id-type="pmid">16527552</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>HG</given-names></string-name>, <string-name><surname>Ai</surname><given-names>YW</given-names></string-name>, <string-name><surname>Yu</surname><given-names>LL</given-names></string-name>, et al. <article-title>Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>2008</year>;<volume>122</volume>(<issue>2</issue>):<fpage>433</fpage>–<lpage>443</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.23049</pub-id><pub-id pub-id-type="pmid">17935137</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Harada</surname><given-names>K</given-names></string-name>, <string-name><surname>Baba</surname><given-names>Y</given-names></string-name>, <string-name><surname>Shigaki</surname><given-names>H</given-names></string-name>, et al. <article-title>Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2016</year>;<volume>16</volume>:<fpage>400</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-016-2422-y</pub-id><pub-id pub-id-type="pmid">27388016</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Oki</surname><given-names>E</given-names></string-name>, <string-name><surname>Baba</surname><given-names>H</given-names></string-name>, <string-name><surname>Tokunaga</surname><given-names>E</given-names></string-name>, et al. <article-title>Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>2005</year>;<volume>117</volume>(<issue>3</issue>):<fpage>376</fpage>–<lpage>380</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(ISSN)1097-0215</pub-id><pub-id pub-id-type="pmid">15900596</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>LL</given-names></string-name>, <string-name><surname>Dai</surname><given-names>N</given-names></string-name>, <string-name><surname>Yu</surname><given-names>HG</given-names></string-name>, <string-name><surname>Sun</surname><given-names>LM</given-names></string-name>, <string-name><surname>Si</surname><given-names>JM</given-names></string-name>. <article-title>Akt associates with nuclear factor kappaB and plays an important role in chemoresistance of gastric cancer cells</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2010</year>;<volume>24</volume>(<issue>1</issue>):<fpage>113</fpage>–<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or_00000835</pub-id><pub-id pub-id-type="pmid">20514451</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Almhanna</surname><given-names>K</given-names></string-name>, <string-name><surname>Cubitt</surname><given-names>CL</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, et al. <article-title>MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines</article-title>. <source><italic toggle="yes">Cancer Biol Ther</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>10</issue>):<fpage>932</fpage>–<lpage>936</lpage>. doi:<pub-id pub-id-type="doi">10.4161/cbt.25939</pub-id><pub-id pub-id-type="pmid">23917345</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Dai</surname><given-names>X</given-names></string-name>, <string-name><surname>Zou</surname><given-names>P</given-names></string-name>, et al. <article-title>Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer</article-title>. <source><italic toggle="yes">Br J Pharmacol</italic></source>. <year>2017</year>;<volume>174</volume>(<issue>10</issue>):<fpage>1131</fpage>–<lpage>1146</lpage>. doi:<pub-id pub-id-type="doi">10.1111/bph.13765</pub-id><pub-id pub-id-type="pmid">28255993</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Smith</surname><given-names>AG</given-names></string-name>, <string-name><surname>Macleod</surname><given-names>KF</given-names></string-name>. <article-title>Autophagy, cancer stem cells and drug resistance</article-title>. <source><italic toggle="yes">J Pathol</italic></source>. <year>2019</year>;<volume>247</volume>(<issue>5</issue>):<fpage>708</fpage>–<lpage>718</lpage>. doi:<pub-id pub-id-type="doi">10.1002/path.2019.247.issue-5</pub-id><pub-id pub-id-type="pmid">30570140</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>Y-J</given-names></string-name>, <string-name><surname>Lei</surname><given-names>Y-H</given-names></string-name>, <string-name><surname>Yao</surname><given-names>N</given-names></string-name>, et al. <article-title>Autophagy and multidrug resistance in cancer</article-title>. <source><italic toggle="yes">Chin J Cancer</italic></source>. <year>2017</year>;<volume>36</volume>(<issue>1</issue>):<fpage>52</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40880-017-0219-2</pub-id><pub-id pub-id-type="pmid">28646911</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Levine</surname><given-names>B</given-names></string-name>, <string-name><surname>Kroemer</surname><given-names>G</given-names></string-name>. <article-title>Autophagy in the pathogenesis of disease</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2008</year>;<volume>132</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2007.12.018</pub-id><pub-id pub-id-type="pmid">18191218</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Mizushima</surname><given-names>N</given-names></string-name>, <string-name><surname>Yoshimori</surname><given-names>T</given-names></string-name>, <string-name><surname>Ohsumi</surname><given-names>Y</given-names></string-name>. <article-title>The role of Atg proteins in autophagosome formation</article-title>. <source><italic toggle="yes">Annu Rev Cell Dev Biol</italic></source>. <year>2011</year>;<volume>27</volume>:<fpage>107</fpage>–<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-cellbio-092910-154005</pub-id><pub-id pub-id-type="pmid">21801009</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Yoshida</surname><given-names>GJ</given-names></string-name>. <article-title>Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment</article-title>. <source><italic toggle="yes">J Hematol Oncol</italic></source>. <year>2017</year>;<volume>10</volume>(<issue>1</issue>):<fpage>67</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13045-017-0436-9</pub-id><pub-id pub-id-type="pmid">28279189</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>White</surname><given-names>E</given-names></string-name>, <string-name><surname>DiPaola</surname><given-names>RS</given-names></string-name>. <article-title>The double-edged sword of autophagy modulation in cancer</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2009</year>;<volume>15</volume>(<issue>17</issue>):<fpage>5308</fpage>–<lpage>5316</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5023</pub-id><pub-id pub-id-type="pmid">19706824</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Kondo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kanzawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Sawaya</surname><given-names>R</given-names></string-name>, <string-name><surname>Kondo</surname><given-names>S</given-names></string-name>. <article-title>The role of autophagy in cancer development and response to therapy</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2005</year>;<volume>5</volume>(<issue>9</issue>):<fpage>726</fpage>–<lpage>734</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc1692</pub-id><pub-id pub-id-type="pmid">16148885</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Amaravadi</surname><given-names>RK</given-names></string-name>, <string-name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></string-name>, <string-name><surname>Yin</surname><given-names>X-M</given-names></string-name>, et al. <article-title>Principles and current strategies for targeting autophagy for cancer treatment</article-title>. <source><italic toggle="yes">Clin Cancer Res</italic></source>. <year>2011</year>;<volume>17</volume>(<issue>4</issue>):<fpage>654</fpage>–<lpage>666</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2634</pub-id><pub-id pub-id-type="pmid">21325294</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zou</surname><given-names>J</given-names></string-name>, et al. <article-title>Autophagy and its role in gastric cancer</article-title>. <source><italic toggle="yes">Clin Chim Acta</italic></source>. <year>2019</year>;<volume>489</volume>:<fpage>10</fpage>–<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cca.2018.11.028</pub-id><pub-id pub-id-type="pmid">30472237</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Qian</surname><given-names>H-R</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y</given-names></string-name>. <article-title>Functional role of autophagy in gastric cancer</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2016</year>;<volume>7</volume>(<issue>14</issue>):<fpage>17641</fpage>–<lpage>17651</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.v7i14</pub-id><pub-id pub-id-type="pmid">26910278</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Al-Akra</surname><given-names>L</given-names></string-name>, <string-name><surname>Bae</surname><given-names>D-H</given-names></string-name>, <string-name><surname>Leck</surname><given-names>LYW</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>DR</given-names></string-name>, <string-name><surname>Jansson</surname><given-names>PJ</given-names></string-name>. <article-title>The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance</article-title>. <source><italic toggle="yes">Biochim Biophys Acta Gen Subj</italic></source>. <year>2019</year>;<volume>1863</volume>(<issue>9</issue>):<fpage>1390</fpage>–<lpage>1397</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbagen.2019.06.007</pub-id><pub-id pub-id-type="pmid">31202693</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Crighton</surname><given-names>D</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>S</given-names></string-name>, <string-name><surname>O’Prey</surname><given-names>J</given-names></string-name>, et al. <article-title>DRAM, a p53-induced modulator of autophagy, is critical for apoptosis</article-title>. <source><italic toggle="yes">Cell</italic></source>. <year>2006</year>;<volume>126</volume>(<issue>1</issue>):<fpage>121</fpage>–<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2006.05.034</pub-id><pub-id pub-id-type="pmid">16839881</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Simon</surname><given-names>H-U</given-names></string-name>, <string-name><surname>Friis</surname><given-names>R</given-names></string-name>, <string-name><surname>Tait</surname><given-names>SWG</given-names></string-name>, <string-name><surname>Ryan</surname><given-names>KM</given-names></string-name>. <article-title>Retrograde signaling from autophagy modulates stress responses</article-title>. <source><italic toggle="yes">Sci Signal</italic></source>. <year>2017</year>;<volume>10</volume>(<issue>468</issue>):<fpage>eaag2791</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scisignal.aag2791</pub-id><pub-id pub-id-type="pmid">28246201</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Levy</surname><given-names>JMM</given-names></string-name>, <string-name><surname>Towers</surname><given-names>CG</given-names></string-name>, <string-name><surname>Thorburn</surname><given-names>A</given-names></string-name>. <article-title>Targeting autophagy in cancer</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2017</year>;<volume>17</volume>(<issue>9</issue>):<fpage>528</fpage>–<lpage>542</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc.2017.53</pub-id><pub-id pub-id-type="pmid">28751651</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Pascolo</surname><given-names>S</given-names></string-name>. <article-title>Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies</article-title>. <source><italic toggle="yes">Eur J Pharmacol</italic></source>. <year>2016</year>;<volume>771</volume>:<fpage>139</fpage>–<lpage>144</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejphar.2015.12.017</pub-id><pub-id pub-id-type="pmid">26687632</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Elliott</surname><given-names>T</given-names></string-name>, <string-name><surname>Sethi</surname><given-names>T</given-names></string-name>. <article-title>Integrins and extracellular matrix: a novel mechanism of multidrug resistance</article-title>. <source><italic toggle="yes">Expert Rev Anticancer Ther</italic></source>. <year>2002</year>;<volume>2</volume>(<issue>4</issue>):<fpage>449</fpage>–<lpage>459</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14737140.2.4.449</pub-id><pub-id pub-id-type="pmid">12647988</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Gilkes</surname><given-names>DM</given-names></string-name>, <string-name><surname>Semenza</surname><given-names>GL</given-names></string-name>, <string-name><surname>Wirtz</surname><given-names>D</given-names></string-name>. <article-title>Hypoxia and the extracellular matrix: drivers of tumour metastasis</article-title>. <source><italic toggle="yes">Nat Rev Cancer</italic></source>. <year>2014</year>;<volume>14</volume>(<issue>6</issue>):<fpage>430</fpage>–<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc3726</pub-id><pub-id pub-id-type="pmid">24827502</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90.</label><mixed-citation publication-type="journal"><string-name><surname>Pickup</surname><given-names>MW</given-names></string-name>, <string-name><surname>Mouw</surname><given-names>JK</given-names></string-name>, <string-name><surname>Weaver</surname><given-names>VM</given-names></string-name>. <article-title>The extracellular matrix modulates the hallmarks of cancer</article-title>. <source><italic toggle="yes">EMBO Rep</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1243</fpage>–<lpage>1253</lpage>. doi:<pub-id pub-id-type="doi">10.15252/embr.201439246</pub-id><pub-id pub-id-type="pmid">25381661</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91.</label><mixed-citation publication-type="journal"><string-name><surname>Nakamura</surname><given-names>K</given-names></string-name>, <string-name><surname>Mori</surname><given-names>M</given-names></string-name>, <string-name><surname>Enjoji</surname><given-names>M</given-names></string-name>. <article-title>Distribution of basement membrane antigens in clinical gastric adenocarcinomas: an immunohistochemical study</article-title>. <source><italic toggle="yes">J Clin Pathol</italic></source>. <year>1987</year>;<volume>40</volume>(<issue>12</issue>):<fpage>1418</fpage>–<lpage>1423</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jcp.40.12.1418</pub-id><pub-id pub-id-type="pmid">3323249</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, et al. <article-title>Gastric cancer cell adhesion to laminin enhances acquired chemotherapeutic drug resistance mediated by MGr1-Ag/37LRP</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2014</year>;<volume>32</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>114</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2014.3184</pub-id><pub-id pub-id-type="pmid">24840404</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, et al. <article-title>MGr1-Ag/37LRP induces cell adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway in gastric cancer</article-title>. <source><italic toggle="yes">Cancer Sci</italic></source>. <year>2014</year>;<volume>105</volume>(<issue>6</issue>):<fpage>651</fpage>–<lpage>659</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cas.12414</pub-id><pub-id pub-id-type="pmid">24703465</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname><given-names>JM</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>Hait</surname><given-names>WN</given-names></string-name>. <article-title>Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells</article-title>. <source><italic toggle="yes">Mol Cancer Res</italic></source>. <year>2003</year>;<volume>1</volume>(<issue>6</issue>):<fpage>420</fpage>–<lpage>427</lpage>.<pub-id pub-id-type="pmid">12692261</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>Yin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>W</given-names></string-name>, <string-name><surname>Deng</surname><given-names>M</given-names></string-name>, et al. <article-title>Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of Pglycoprotein expression in gastric adenocarcinoma cells</article-title>. <source><italic toggle="yes">Mol Med Rep</italic></source>. <year>2014</year>;<volume>9</volume>(<issue>4</issue>):<fpage>1439</fpage>–<lpage>1443</lpage>. doi:<pub-id pub-id-type="doi">10.3892/mmr.2014.1961</pub-id><pub-id pub-id-type="pmid">24549588</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>Ock</surname><given-names>CY</given-names></string-name>, <string-name><surname>Nam</surname><given-names>AR</given-names></string-name>, <string-name><surname>Bang</surname><given-names>JH</given-names></string-name>, et al. <article-title>Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer</article-title>. <source><italic toggle="yes">Gastric Cancer</italic></source>. <year>2017</year>;<volume>20</volume>(<issue>1</issue>):<fpage>164</fpage>–<lpage>174</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10120-015-0583-z</pub-id><pub-id pub-id-type="pmid">26681196</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>D</given-names></string-name>, et al. <article-title>Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2015</year>;<volume>6</volume>(<issue>7</issue>):<fpage>5072</fpage>–<lpage>5087</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.3241</pub-id><pub-id pub-id-type="pmid">25669984</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98.</label><mixed-citation publication-type="journal"><string-name><surname>Ye</surname><given-names>XL</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>YR</given-names></string-name>, <string-name><surname>Weng</surname><given-names>GB</given-names></string-name>, et al. <article-title>IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2015</year>;<volume>33</volume>(<issue>6</issue>):<fpage>2746</fpage>–<lpage>2752</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2015.3898</pub-id><pub-id pub-id-type="pmid">25846650</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99.</label><mixed-citation publication-type="journal"><string-name><surname>Mao</surname><given-names>Z</given-names></string-name>, <string-name><surname>Bian</surname><given-names>G</given-names></string-name>, <string-name><surname>Sheng</surname><given-names>W</given-names></string-name>, <string-name><surname>He</surname><given-names>S</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X</given-names></string-name>. <article-title>Adenovirus-mediated IL-24 expression enhances the chemosensitivity of multidrug-resistantgastric cancer cells to cisplatin</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2013</year>;<volume>30</volume>(<issue>5</issue>):<fpage>2288</fpage>–<lpage>2296</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2013.2695</pub-id><pub-id pub-id-type="pmid">23982423</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>J</given-names></string-name>, et al. <article-title>HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2014</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e90678</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0090678</pub-id><pub-id pub-id-type="pmid">24614305</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101.</label><mixed-citation publication-type="journal"><string-name><surname>Isobe</surname><given-names>T</given-names></string-name>, <string-name><surname>Aoyagi</surname><given-names>K</given-names></string-name>, <string-name><surname>Koufuji</surname><given-names>K</given-names></string-name>, et al. <article-title>Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1alpha) expression in gastric cancer</article-title>. <source><italic toggle="yes">Int J Clin Oncol</italic></source>. <year>2013</year>;<volume>18</volume>(<issue>2</issue>):<fpage>293</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">22350022</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname><given-names>CL</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CH</given-names></string-name>, <string-name><surname>Lin</surname><given-names>XS</given-names></string-name>, <string-name><surname>Xie</surname><given-names>F</given-names></string-name>. <article-title>Prognostic value of HIF-1alpha expression in patients with gastric cancer</article-title>. <source><italic toggle="yes">Mol Biol Rep</italic></source>. <year>2013</year>;<volume>40</volume>(<issue>11</issue>):<fpage>6055</fpage>–<lpage>6062</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11033-013-2715-z</pub-id><pub-id pub-id-type="pmid">24057269</pub-id></mixed-citation></ref><ref id="CIT0103"><label>103.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Ning</surname><given-names>X</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L</given-names></string-name>, et al. <article-title>Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer</article-title>. <source><italic toggle="yes">Cancer Sci</italic></source>. <year>2008</year>;<volume>99</volume>(<issue>1</issue>):<fpage>121</fpage>–<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1349-7006.2007.00643.x</pub-id><pub-id pub-id-type="pmid">17953712</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104.</label><mixed-citation publication-type="journal"><string-name><surname>Rohwer</surname><given-names>N</given-names></string-name>, <string-name><surname>Dame</surname><given-names>C</given-names></string-name>, <string-name><surname>Haugstetter</surname><given-names>A</given-names></string-name>, et al. <article-title>Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2010</year>;<volume>5</volume>(<issue>8</issue>):<fpage>e12038</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0012038</pub-id><pub-id pub-id-type="pmid">20706634</pub-id></mixed-citation></ref><ref id="CIT0105"><label>105.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>XP</given-names></string-name>, <string-name><surname>Dong</surname><given-names>X</given-names></string-name>, <string-name><surname>Lin</surname><given-names>L</given-names></string-name>, et al. <article-title>Up-regulation of survivin by AKT and hypoxia-inducible factor 1alpha contributes to cisplatin resistance in gastric cancer</article-title>. <source><italic toggle="yes">FEBS J</italic></source>. <year>2014</year>;<volume>281</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>128</lpage>. doi:<pub-id pub-id-type="doi">10.1111/febs.12577</pub-id><pub-id pub-id-type="pmid">24165223</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L</given-names></string-name>, et al. <article-title>ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>2010</year>;<volume>127</volume>(<issue>4</issue>):<fpage>820</fpage>–<lpage>829</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.25098</pub-id><pub-id pub-id-type="pmid">19998339</pub-id></mixed-citation></ref><ref id="CIT0107"><label>107.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname><given-names>T</given-names></string-name>, <string-name><surname>Song</surname><given-names>C</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name>, <string-name><surname>Xia</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>. <article-title>The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy</article-title>. <source><italic toggle="yes">Mol Cancer</italic></source>. <year>2019</year>;<volume>18</volume>(<issue>1</issue>):<fpage>62</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12943-019-0967-5</pub-id><pub-id pub-id-type="pmid">30925929</pub-id></mixed-citation></ref><ref id="CIT0108"><label>108.</label><mixed-citation publication-type="journal"><string-name><surname>Schorey</surname><given-names>JS</given-names></string-name>, <string-name><surname>Bhatnagar</surname><given-names>S</given-names></string-name>. <article-title>Exosome function: from tumor immunology to pathogen biology</article-title>. <source><italic toggle="yes">Traffic</italic></source>. <year>2008</year>;<volume>9</volume>(<issue>6</issue>):<fpage>871</fpage>–<lpage>881</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00734.x</pub-id><pub-id pub-id-type="pmid">18331451</pub-id></mixed-citation></ref><ref id="CIT0109"><label>109.</label><mixed-citation publication-type="journal"><string-name><surname>Skog</surname><given-names>J</given-names></string-name>, <string-name><surname>Wurdinger</surname><given-names>T</given-names></string-name>, <string-name><surname>van Rijn</surname><given-names>S</given-names></string-name>, et al. <article-title>Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers</article-title>. <source><italic toggle="yes">Nat Cell Biol</italic></source>. <year>2008</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1470</fpage>–<lpage>1476</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ncb1800</pub-id><pub-id pub-id-type="pmid">19011622</pub-id></mixed-citation></ref><ref id="CIT0110"><label>110.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Qiu</surname><given-names>R</given-names></string-name>, <string-name><surname>Yu</surname><given-names>S</given-names></string-name>, et al. <article-title>Paclitaxelresistant gastric cancer MGC803 cells promote epithelialtomesenchymal transition and chemoresistance in paclitaxelsensitive cells via exosomal delivery of miR1555p</article-title>. <source><italic toggle="yes">Int J Oncol</italic></source>. <year>2019</year>;<volume>54</volume>(<issue>1</issue>):<fpage>326</fpage>–<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ijo.2018.4601</pub-id><pub-id pub-id-type="pmid">30365045</pub-id></mixed-citation></ref><ref id="CIT0111"><label>111.</label><mixed-citation publication-type="journal"><string-name><surname>Ji</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, et al. <article-title>Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer</article-title>. <source><italic toggle="yes">Cell Cycle</italic></source>. <year>2015</year>;<volume>14</volume>(<issue>15</issue>):<fpage>2473</fpage>–<lpage>2483</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15384101.2015.1005530</pub-id><pub-id pub-id-type="pmid">26091251</pub-id></mixed-citation></ref><ref id="CIT0112"><label>112.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>P</given-names></string-name>, <string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>X</given-names></string-name>, et al. <article-title>Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2017</year>;<volume>36</volume>(<issue>1</issue>):<fpage>53</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-017-0528-y</pub-id><pub-id pub-id-type="pmid">28407783</pub-id></mixed-citation></ref><ref id="CIT0113"><label>113.</label><mixed-citation publication-type="journal"><string-name><surname>Ha</surname><given-names>KD</given-names></string-name>, <string-name><surname>Bidlingmaier</surname><given-names>SM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>B</given-names></string-name>. <article-title>Macropinocytosis exploitation by cancers and cancer therapeutics</article-title>. <source><italic toggle="yes">Front Physiol</italic></source>. <year>2016</year>;<volume>7</volume>:<fpage>381</fpage>.<pub-id pub-id-type="pmid">27672367</pub-id></mixed-citation></ref><ref id="CIT0114"><label>114.</label><mixed-citation publication-type="journal"><string-name><surname>Vander Heiden</surname><given-names>MG</given-names></string-name>, <string-name><surname>Cantley</surname><given-names>LC</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>CB</given-names></string-name>. <article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title>. <source><italic toggle="yes">Science (New York, NY)</italic></source>. <year>2009</year>;<volume>324</volume>(<issue>5930</issue>):<fpage>1029</fpage>–<lpage>1033</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1160809</pub-id></mixed-citation></ref><ref id="CIT0115"><label>115.</label><mixed-citation publication-type="journal"><string-name><surname>Pavlova</surname><given-names>NN</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>CB</given-names></string-name>. <article-title>The emerging hallmarks of cancer metabolism</article-title>. <source><italic toggle="yes">Cell Metab</italic></source>. <year>2016</year>;<volume>23</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>47</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.006</pub-id><pub-id pub-id-type="pmid">26771115</pub-id></mixed-citation></ref><ref id="CIT0116"><label>116.</label><mixed-citation publication-type="journal"><string-name><surname>Qian</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Extracellular ATP is internalized by macropinocytosis and induces intracellular ATP increase and drug resistance in cancer cells</article-title>. <source><italic toggle="yes">Cancer Lett</italic></source>. <year>2014</year>;<volume>351</volume>(<issue>2</issue>):<fpage>242</fpage>–<lpage>251</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2014.06.008</pub-id><pub-id pub-id-type="pmid">24973521</pub-id></mixed-citation></ref><ref id="CIT0117"><label>117.</label><mixed-citation publication-type="journal"><string-name><surname>Cullis</surname><given-names>J</given-names></string-name>, <string-name><surname>Siolas</surname><given-names>D</given-names></string-name>, <string-name><surname>Avanzi</surname><given-names>A</given-names></string-name>, <string-name><surname>Barui</surname><given-names>S</given-names></string-name>, <string-name><surname>Maitra</surname><given-names>A</given-names></string-name>, <string-name><surname>Bar-Sagi</surname><given-names>D</given-names></string-name>. <article-title>Macropinocytosis of Nab-paclitaxel drives macrophage activation in pancreatic cancer</article-title>. <source><italic toggle="yes">Cancer Immunol Res</italic></source>. <year>2017</year>;<volume>5</volume>(<issue>3</issue>):<fpage>182</fpage>–<lpage>190</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-16-0125</pub-id><pub-id pub-id-type="pmid">28108630</pub-id></mixed-citation></ref><ref id="CIT0118"><label>118.</label><mixed-citation publication-type="journal"><string-name><surname>Werfel</surname><given-names>TA</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>MA</given-names></string-name>, et al. <article-title>Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival</article-title>. <source><italic toggle="yes">Cancer Res</italic></source>. <year>2018</year>;<volume>78</volume>(<issue>7</issue>):<fpage>1845</fpage>–<lpage>1858</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2388</pub-id><pub-id pub-id-type="pmid">29358172</pub-id></mixed-citation></ref><ref id="CIT0119"><label>119.</label><mixed-citation publication-type="journal"><string-name><surname>Di Leva</surname><given-names>G</given-names></string-name>, <string-name><surname>Garofalo</surname><given-names>M</given-names></string-name>, <string-name><surname>Croce</surname><given-names>CM</given-names></string-name>. <article-title>MicroRNAs in cancer</article-title>. <source><italic toggle="yes">Annu Rev Pathol</italic></source>. <year>2014</year>;<volume>9</volume>:<fpage>287</fpage>–<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-pathol-012513-104715</pub-id><pub-id pub-id-type="pmid">24079833</pub-id></mixed-citation></ref><ref id="CIT0120"><label>120.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>PF</given-names></string-name>, <string-name><surname>Chen</surname><given-names>SC</given-names></string-name>, <string-name><surname>Xia</surname><given-names>T</given-names></string-name>, et al. <article-title>Non-coding RNAs and gastric cancer</article-title>. <source><italic toggle="yes">World J Gastroenterol</italic></source>. <year>2014</year>;<volume>20</volume>(<issue>18</issue>):<fpage>5411</fpage>–<lpage>5419</lpage>. doi:<pub-id pub-id-type="doi">10.3748/wjg.v20.i18.5411</pub-id><pub-id pub-id-type="pmid">24833871</pub-id></mixed-citation></ref><ref id="CIT0121"><label>121.</label><mixed-citation publication-type="journal"><string-name><surname>Gu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Chen</surname><given-names>T</given-names></string-name>, <string-name><surname>Li</surname><given-names>G</given-names></string-name>, et al. <article-title>LncRNAs: emerging biomarkers in gastric cancer</article-title>. <source><italic toggle="yes">Future Oncol</italic></source>. <year>2015</year>;<volume>11</volume>(<issue>17</issue>):<fpage>2427</fpage>–<lpage>2441</lpage>. doi:<pub-id pub-id-type="doi">10.2217/fon.15.175</pub-id><pub-id pub-id-type="pmid">26289363</pub-id></mixed-citation></ref><ref id="CIT0122"><label>122.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>T</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>. <article-title>Role of microRNA in anticancer drug resistance</article-title>. <source><italic toggle="yes">Int J Cancer</italic></source>. <year>2010</year>;<volume>126</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>10</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.v126:1</pub-id><pub-id pub-id-type="pmid">19634138</pub-id></mixed-citation></ref><ref id="CIT0123"><label>123.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name><surname>Ge</surname><given-names>G</given-names></string-name>, <string-name><surname>Ding</surname><given-names>Y</given-names></string-name>, et al. <article-title>MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2</article-title>. <source><italic toggle="yes">Chin Med J</italic></source>. <year>2014</year>;<volume>127</volume>(<issue>12</issue>):<fpage>2357</fpage>–<lpage>2362</lpage>.<pub-id pub-id-type="pmid">24931256</pub-id></mixed-citation></ref><ref id="CIT0124"><label>124.</label><mixed-citation publication-type="journal"><string-name><surname>Zhuang</surname><given-names>M</given-names></string-name>, <string-name><surname>Shi</surname><given-names>Q</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, et al. <article-title>Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2</article-title>. <source><italic toggle="yes">Tumour Biol</italic></source>. <year>2015</year>;<volume>36</volume>(<issue>4</issue>):<fpage>2737</fpage>–<lpage>2745</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13277-014-2898-5</pub-id><pub-id pub-id-type="pmid">25492481</pub-id></mixed-citation></ref><ref id="CIT0125"><label>125.</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname><given-names>W</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>D</given-names></string-name>, et al. <article-title>miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP</article-title>. <source><italic toggle="yes">Cancer Chemother Pharmacol</italic></source>. <year>2012</year>;<volume>69</volume>(<issue>3</issue>):<fpage>723</fpage>–<lpage>731</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00280-011-1752-3</pub-id><pub-id pub-id-type="pmid">21993663</pub-id></mixed-citation></ref><ref id="CIT0126"><label>126.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname><given-names>SM</given-names></string-name>, <string-name><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>XF</given-names></string-name>, <string-name><surname>Yu</surname><given-names>MZ</given-names></string-name>, <string-name><surname>He</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>. <article-title>miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN</article-title>. <source><italic toggle="yes">Toxicology</italic></source>. <year>2013</year>;<volume>306</volume>:<fpage>162</fpage>–<lpage>168</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tox.2013.02.014</pub-id><pub-id pub-id-type="pmid">23466500</pub-id></mixed-citation></ref><ref id="CIT0127"><label>127.</label><mixed-citation publication-type="journal"><string-name><surname>Eto</surname><given-names>K</given-names></string-name>, <string-name><surname>Iwatsuki</surname><given-names>M</given-names></string-name>, <string-name><surname>Watanabe</surname><given-names>M</given-names></string-name>, et al. <article-title>The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab</article-title>. <source><italic toggle="yes">Ann Surg Oncol</italic></source>. <year>2014</year>;<volume>21</volume>(<issue>1</issue>):<fpage>343</fpage>–<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1245/s10434-013-3325-7</pub-id><pub-id pub-id-type="pmid">24154840</pub-id></mixed-citation></ref><ref id="CIT0128"><label>128.</label><mixed-citation publication-type="journal"><string-name><surname>Hu</surname><given-names>N</given-names></string-name>, <string-name><surname>Yin</surname><given-names>JF</given-names></string-name>, <string-name><surname>Ji</surname><given-names>Z</given-names></string-name>, et al. <article-title>Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-MiR-21 and 5-fluorouridine</article-title>. <source><italic toggle="yes">Cell Physiol Biochem</italic></source>. <year>2017</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2158</fpage>–<lpage>2173</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000485955</pub-id><pub-id pub-id-type="pmid">29241186</pub-id></mixed-citation></ref><ref id="CIT0129"><label>129.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>XM</given-names></string-name>, <string-name><surname>Shao</surname><given-names>XQ</given-names></string-name>, <string-name><surname>Meng</surname><given-names>XX</given-names></string-name>, et al. <article-title>Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells</article-title>. <source><italic toggle="yes">Acta Pharmacol Sin</italic></source>. <year>2011</year>;<volume>32</volume>(<issue>2</issue>):<fpage>259</fpage>–<lpage>269</lpage>. doi:<pub-id pub-id-type="doi">10.1038/aps.2010.204</pub-id><pub-id pub-id-type="pmid">21293479</pub-id></mixed-citation></ref><ref id="CIT0130"><label>130.</label><mixed-citation publication-type="journal"><string-name><surname>Kim</surname><given-names>CH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>HK</given-names></string-name>, <string-name><surname>Rettig</surname><given-names>RL</given-names></string-name>, et al. <article-title>miRNA signature associated with outcome of gastric cancer patients following chemotherapy</article-title>. <source><italic toggle="yes">BMC Med Genomics</italic></source>. <year>2011</year>;<volume>4</volume>:<fpage>79</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1755-8794-4-79</pub-id><pub-id pub-id-type="pmid">22112324</pub-id></mixed-citation></ref><ref id="CIT0131"><label>131.</label><mixed-citation publication-type="journal"><string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Gong</surname><given-names>M</given-names></string-name>, et al. <article-title>Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer</article-title>. <source><italic toggle="yes">Onco Targets Ther</italic></source>. <year>2014</year>;<volume>7</volume>:<fpage>1625</fpage>–<lpage>1630</lpage>. doi:<pub-id pub-id-type="doi">10.2147/OTT</pub-id><pub-id pub-id-type="pmid">25258543</pub-id></mixed-citation></ref><ref id="CIT0132"><label>132.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>DD</given-names></string-name>, <string-name><surname>Liu</surname><given-names>XF</given-names></string-name>, <string-name><surname>Lu</surname><given-names>CW</given-names></string-name>, <string-name><surname>Pant</surname><given-names>OP</given-names></string-name>, <string-name><surname>Liu</surname><given-names>XD</given-names></string-name>. <article-title>Long non-coding RNA PVT1: emerging biomarker in digestive system cancer</article-title>. <source><italic toggle="yes">Cell Prolif</italic></source>. <year>2017</year>;<volume>50</volume>(<issue>6</issue>):<fpage>e12398</fpage>. doi:<pub-id pub-id-type="doi">10.1111/cpr.12398</pub-id></mixed-citation></ref><ref id="CIT0133"><label>133.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>XW</given-names></string-name>, <string-name><surname>Bu</surname><given-names>P</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XZ</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>. <article-title>Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance</article-title>. <source><italic toggle="yes">Biochem Biophys Res Commun</italic></source>. <year>2015</year>;<volume>462</volume>(<issue>3</issue>):<fpage>227</fpage>–<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2015.04.121</pub-id><pub-id pub-id-type="pmid">25956062</pub-id></mixed-citation></ref><ref id="CIT0134"><label>134.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>XW</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XZ</given-names></string-name>, <string-name><surname>Bo</surname><given-names>P</given-names></string-name>. <article-title>Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells</article-title>. <source><italic toggle="yes">Exp Ther Med</italic></source>. <year>2017</year>;<volume>14</volume>(<issue>2</issue>):<fpage>1789</fpage>–<lpage>1794</lpage>. doi:<pub-id pub-id-type="doi">10.3892/etm.2017.4650</pub-id><pub-id pub-id-type="pmid">28810651</pub-id></mixed-citation></ref><ref id="CIT0135"><label>135.</label><mixed-citation publication-type="journal"><string-name><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ye</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>D</given-names></string-name>, et al. <article-title>LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2014</year>;<volume>14</volume>:<fpage>932</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1471-2407-14-932</pub-id><pub-id pub-id-type="pmid">25496320</pub-id></mixed-citation></ref><ref id="CIT0136"><label>136.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Q</given-names></string-name>, <string-name><surname>Nie</surname><given-names>Y</given-names></string-name>, <string-name><surname>Fan</surname><given-names>D</given-names></string-name>. <article-title>Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines</article-title>. <source><italic toggle="yes">Mol Cell Biol</italic></source>. <year>2014</year>;<volume>34</volume>(<issue>17</issue>):<fpage>3182</fpage>–<lpage>3193</lpage>. doi:<pub-id pub-id-type="doi">10.1128/MCB.01580-13</pub-id><pub-id pub-id-type="pmid">24958102</pub-id></mixed-citation></ref><ref id="CIT0137"><label>137.</label><mixed-citation publication-type="journal"><string-name><surname>Hang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>. <article-title>Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression</article-title>. <source><italic toggle="yes">Anticancer Drugs</italic></source>. <year>2015</year>;<volume>26</volume>(<issue>6</issue>):<fpage>632</fpage>–<lpage>640</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CAD.0000000000000227</pub-id><pub-id pub-id-type="pmid">25763542</pub-id></mixed-citation></ref><ref id="CIT0138"><label>138.</label><mixed-citation publication-type="journal"><string-name><surname>Yan</surname><given-names>J</given-names></string-name>, <string-name><surname>Dang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>. <article-title>LncRNA HOTAIR promotes cisplatin resistance in gastric cancer by targeting miR-126 to activate the PI3K/AKT/MRP1 genes</article-title>. <source><italic toggle="yes">Tumour Biol</italic></source>. <year>2016</year>;<volume>37</volume>:<fpage>16345</fpage>–<lpage>16355</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13277-016-5448-5</pub-id></mixed-citation></ref><ref id="CIT0139"><label>139.</label><mixed-citation publication-type="journal"><string-name><surname>Fang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhi</surname><given-names>X</given-names></string-name>. <article-title>Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b</article-title>. <source><italic toggle="yes">Med Sci Monit</italic></source>. <year>2016</year>;<volume>22</volume>:<fpage>3506</fpage>–<lpage>3513</lpage>. doi:<pub-id pub-id-type="doi">10.12659/MSM.900688</pub-id><pub-id pub-id-type="pmid">27694794</pub-id></mixed-citation></ref><ref id="CIT0140"><label>140.</label><mixed-citation publication-type="journal"><string-name><surname>Tang</surname><given-names>HN</given-names></string-name>, <string-name><surname>Hu</surname><given-names>JH</given-names></string-name>. <article-title>A comparison of surgical procedures and postoperative cares for minimally invasive laparoscopic gastrectomy and open gastrectomy in gastric cancer</article-title>. <source><italic toggle="yes">Int J Clin Exp Med</italic></source>. <year>2015</year>;<volume>8</volume>(<issue>7</issue>):<fpage>10321</fpage>–<lpage>10329</lpage>.<pub-id pub-id-type="pmid">26379823</pub-id></mixed-citation></ref><ref id="CIT0141"><label>141.</label><mixed-citation publication-type="journal"><string-name><surname>Song</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J</given-names></string-name>, <string-name><surname>Yang</surname><given-names>D</given-names></string-name>, <string-name><surname>Fang</surname><given-names>X</given-names></string-name>. <article-title>Progress in the treatment of advanced gastric cancer</article-title>. <source><italic toggle="yes">Tumour Biol</italic></source>. <year>2017</year>;<volume>39</volume>(<issue>7</issue>):<fpage>1010428317714626</fpage>. doi:<pub-id pub-id-type="doi">10.1177/1010428317714626</pub-id><pub-id pub-id-type="pmid">28671042</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7053652
|texte= A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32184615" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |